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Individual septic systems and wastewater treatment plants (WWTP) are used to collect 
and treat sewage. Concern has been raised as to the fate o f pharmaceuticals and personal 
care products found in sewage, yet their fate in household or community septic systems is 
poorly known. The use o f septic tanks is widespread as approximately 25-35% of homes 
rely on them for waste disposal. This study attempts to characterize the occurrence and 
estimate concentrations of pharmaceuticals in septic system effluent, and examine the 
potential for the contamination of shallow aquifers. Sewage entering a wastewater 
treatment plant was also sampled. The occurrence of 19 drug residues and three drug 
metabolites o f both prescription and non-prescription drugs in wastewater, ground water 
and surface water were analyzed by Time-of-Flight High Performance Liquid 
Chromatography/ Mass Spectrometry (ToF-HPLC-MS). Target compounds were 
acetaminophen, antipyrine, caffeine, carbamazepine, cimetidine, codeine, cotinine, 
diltiazem, erythromycin-18, fenofibrate, fluoxetine, hydrocodone, ketoprofen, metformin, 
nicotine, nifedipine, paraxanthine, ranitidine, salbutamol, sulfamethoxazole, trimethoprim 
and warfarin. Of all raw sewage samples, only 18 of the 22 pharmaceutical compounds 
were present in septic tanks, 12 were detected in WWTP influent, and nine were detected 
in WWTP effluent. The most frequently detected (>50%) non-prescription drugs in the 
raw sewage samples were acetaminophen, caffeine, nicotine and a caffeine metabolite 
(paraxanthine), and a nicotine metabolite (cotinine) These compounds occurred at 
concentrations that were estimated to be higher than 1570-ug/L, 500-ug/L, 100-ug/L, 
1000-ug/L, and 100-ug/L, respectfully. Prescription drugs examined in the raw sewage 
were detected in about 30% of the samples with the exception of warfarin which was 
detected in approximately 77% of the samples. Other frequently detected prescription 
drugs were codeine, trimethoprim and carbamazepine. Ground water receiving septic 
effluent from a high school drain field contained measurable quantities o f caffeine, 
carbamazepine and sulfamethoxazole (<210-ng/mL). Samples o f shallow ground water 
within the unconfined aquifer underlying the city o f Missoula and the adjacent county 
exhibited detectable concentrations of caffeine, carbamazepine, cotinine and 
trimethoprim.
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INTRODUCTION
During the last three decades, an increased focus on water pollution from organic 
chemicals such as toxic/carcinogenic pesticides and industrial byproducts has emerged 
(Christensen 1998). In recent years, pharmaceuticals and personal care products 
(PPCP’s) and their metabolites are appearing in surface water, ground water and drinking 
water as a result o f wastewater contamination (Raloff 1998; Buser et al. 1999; Hartig et 
al. 1999; Seiler et al. 1999; Heberer 2002a and 2002b; Holm et al. 1995; Kolpin et al. 
2002; Scheytt et al. 1998; Eckel et al. 1998; McQuillan et al. 2000, Buerge et al. 2003; 
Clara et al. 2004; Petrovic et al. 2003). Human, industrial and agricultural wastewaters 
contain low levels o f antibiotics, prescription and non-prescription drugs, hormones, 
synthetic steroids, stimulants, detergent metabolites, fire retardants and personal care 
products. This includes compounds such as sulfamethoxazole, carbamazepine, 
acetaminophen, 17[3-estradiol, coprostanol, caffeine, 4-nonylphenol monoethoxylate,
tri(2-chlorethyl) phosphate and acetophenone, respectively (Temes et al. 1998; Seiler et 
al. 1999; Daughton and Temes 1999; Hirsch et al. 1998; Jones-Lepp et al. 2001; Huang 
and Sedlack 2001 ; Temes et al. 2001 ; Kolpin et al. 2002).
To evaluate the pharmaceuticals released into the aquatic environment, studies 
have estimated the amount o f prescription and non-prescription dmgs consumed each 
year (Buerge et al. 2003, Temes 1998; Hirsh 1998; Fisher and Boland, 2003). Hirsh et al. 
(1998) estimated German annual production o f antibiotics to be in the range o f 2000 tons 
per year, while Fisher and Borland (2003) estimated 56 tons per year o f prescription 
dmgs were sold in Sydney, Australia. In the United States 22,680 tons o f antibiotics are 
prescribed annually (Levy 1998). However, prescription dmg estimates are only a small
portion o f the pharmaceuticals used on a daily basis. Large quantities o f non-prescription 
drugs are sold without regulation through out the world (Christensen 1998). It is 
estimated that 1 0 0 0  tons per year o f ibuprofen are consumed in countries such as the 
United Kingdom and Germany. Globally caffeine average consumption (estimated from 
consumption of coffee, tea and soft drinks) is about 70-mg per person per day (Buerge et 
al. 2003). Both prescription and non-prescription drugs are beginning to be detected in 
water systems all over the world.
Recent Studies of Pharmaceuticals in the Environment
Over 20 years ago the first report of pharmaceutically active compounds found 
in sewage influent and effluent were clofibric acid, nicotine and caffeine. These 
compounds were reported to re-enter and persist in the aquatic environment from 
wastewater contamination (Daughton and Temes 1999) (Appendix 1- Pathways of 
Pharmaceuticals in the Environment and Expanded Data for Analytical Difficulties). In 
recent studies on German sewage effluent, eighty percent o f the human dmgs studied, 
were detected in the part per billion range (Temes 1998). In southwestem United States, 
Drewes et al. (2003) reported carbamazepine, primidone, ibuprofen, and naproxen to be 
commonly found in secondary and tertiary treated wastewater effluents and in surface 
water. Drewes et al. (2003) reported that antiepileptic dmgs (such as carbamazepine and 
primidone) persisted in ground water under both anoxic and aerobic conditions. A 
literature review o f 22 targeted pharmaceuticals detected in WWTP influent and effluent, 
surface water and ground water are reported (Table 1).
Table 1. Literature search of pharmaceuticals in surface and ground water, sewage
influent and e f luent
C om p oun d
S u rface W ater and G round W ater (m axim um  reported  
con centration )
R aw  S e w a g e  
WWTP (Max 
R eported  
C on cen tration s)
O utflow  WWTP 
(m ax. reported  
co n cen tra tio n s)
Acetam inophen
Kolpin et al. 2002 (10 ug/L); Verstraeten et al. DRAFT 
(GW*-0.015 ug/L) NF**
T ernes 1998  
(6.0ug/L)
Antipyrine Ternes 1998 (0.95 ug/L) NF** NF**
Caffeine
Seiler et al. 1999 (0.23 ug/L); Mcquillan et al. 2001(1.5  
ug/L); Kolpin et al. 2002 (6.0 ug/L); Buerge et al. 2003 (250  
ng/L); Clara et al. 2004 (0.10 ug/L); Sacher et al. (900 
ng/L); Ternes et al. 2001 (0.88 ug/L); Buerge et al. 2003  
(several different studies 100, 1440, 115, 47. 6000, 370, 
880 1270, 171, 160, 2400 ng/L GW*- 80, 230ng/L); 
Verstraeten et al. DRAFT (GW*-0.12 ug/L); McQuillan et 
al. 2003 (1500 ng/L)
Ternes et al. 2001 
(1.9 ug/L); Heberer, 
2002 (640ug/L); 
Buerge et al. 2003  
(several studies 73, 
300, 20 and 
147ug/L); Benotti el 
al. 2003 (109ng/L)
Heberer, 2002  
(3ug/L) Buerge et al. 
2003 (several 
studies 9480, 0.08, 
6.7, 0 .19  and 2ug/L), 
D rewes et al. 2003  
(15700 ng/L); 
McQuillan et al. 2003  
(1000 ng/L)
Carbam azepine
Ternes 1998 (1.1 ug/L), Heberer 2002 (7.3ug/L); Drewes et 
al. 2003 (235 ng/L); Clara et al. 2004 (GW* 900ng/L)
Heberer, 2002  
(3.8ug/L); Benotti et 
al. 2003 (119ng/L); 
Clara et al. 2004  
(2000ng/L)
D rew es et al. 2003  
(610 ng/L); Heberer, 
2002 (5ug/L) Ternes 
1998 (6.3 ug/L); 
Clara et al. 2004  
(1510ng/L)
Cimetidine Kolpin et al. 2002 (0.58 ug/l)
Benotti et al. 2003  
(240 ng/L) NF**
C odeine Verstraeten et al. DRAFT (GW‘-0.080 ug/L) NF** NF**
Cotinine Verstraeten et al. DRAFT (GW*-0.060 ug/L)
Benotti et al. 2003  
(22 ng/L) NF**
Diltiazem
Kolpin et al. 2002 (0.049 ug/L); Clara et al. 2004 (0.033  
ug/L); Ternes et al. 2001 (0.033 ug/L)
T ernes et al. 2001 
(0 .053 ug/L); 
Benotti et al. 2003  
(52.4 ng/L) NF**
Erythromycin-18
Kolpin et al. 2002 (1.7ug/L); Castiglioni et al. 2004 (15.9  
ng/L); Sacher et al. 2001 (ng/mL); Verstraeten et al. 
DRAFT (GW*-0.75 ug/L) NF** NF**
Fenofibrate NF**
Zwiener et al. 2000  
(1.19ug/L)
Zwiener et al. 2000  
(0.17 ug/L); Ternes 
1998 (0.03 ug/L); 
D rewes et al. 2003  
(35 ng/L)
Fluoxetine Kolpin et al. 2002 (0.012ug/L) NF** NF**
Hydrocodone NF** NF** NF**
Ketoprofen Ternes, 1998 (0.12 ug/L) NF**
D rewes et al. 2003  
(45 ng/L); Ternes 
1998 (0.12 ug/L);
Metformin Kolpin et al. 2002 (0.15 ug/L) NF** NF**
Nicotine NF** NF** NF**
Nifedipine NF**
Ternes et al. 2001 
(0 .089 ug/L) NF**
Paraxanthine (1,7- 
dimethylanthine) Kolpin et al. 2002 (3.1 ug/L) Called 1,7-dimethylxanthine
Benotti et al. 2003  
(154 ng/L) NF**
Ranitidine
Kolpin et al. 2002 (0.01 ug/L); Castiglioni et al. 2004(0 .002  
ug/L),
Benotti et al. 2003  
(91 ng/L) NF**
Salbutamol Ternes, 1998 (0.035 ug/L) Castiglioni et al. 2004 (4.6ng/L)
Benotti et al. 2003  
(35.6 ng/L) NF**
Sulfam ethoxazole
Kolpin et al. 2002 (1.9 and 0.52 ug/L) Sacher et al. 2001 
(410 ng/L), Castiglioni et al. 2004 (0.9ng/L); Verstraeten et 
al. DRAFT (GW*-0.15 ug/L); Hartig et al., 2000(231 ng/L)
Benotti et al. 2003  
(458 ng/L)
Hartig et al. 2000  
(799ng/L)
Trimethoprim
Kolpin et al. 2002 (0.3 ug/L); Verstraeten et al. DRAFT 
(GW*-0.58 ug/L)
Benotti et al. 2003  
(105nq/L) NF
Warfarin Verstraeten et al. DRAFT (GW* 0.009 ug/L) NF** NF**
G W *=ground w ater N F**= not found In literature search or not analyzed
Pharmaceuticals in surface water may impact aquatic biota, raising concern over 
their presence. A reproductive hormone 17P-estradiol, detected in the outfall o f sewage 
treatment plants, negatively impact fish reproductive systems at trace levels (Huang and 
Sedlak 2001; Sedlak et al. 2000; Plesner et al. 2002). Daughton and Temes (1999) 
suggested that humans exposed to trace concentrations of biologically active drugs, for 
example synthetic antibiotic medicines such as sulfonamides, could also suffer adverse 
impacts. Long-term exposure o f non-target organisms to trace concentrations of 
antibiotics may contribute to the maintenance and spread o f antibiotic resistance (Levy 
1998).
To date, efforts have focused on the detection and fate o f pharmaceuticals in 
surface water. The U.S.G.S recently sampled 139 streams in 30 states for compounds 
including plasticizers, pharmaceuticals and hormones (Kolpin et al. 2002). O f the 95 
wastewater contaminants examined, one or more compounds were present in 80% of the 
streams or rivers tested. Only a few studies (e.g. Holm et al. 1995, Umari et al. 1995, 
Eckel et al. 1998, Seiler et al. 1999, Drewes et al. 2003, Verstraeten et al. Draft, Benotti 
et al. 2003) have examined the concentration o f pharmaceuticals in raw sewage. To date, 
no published research has examined PPCP concentrations from individual septic systems 
(Verstraeten et ai. 2004). According to Knowles (1998), approximately 10% of septic 
tanks in the United States are malfunctioning: over 7000 faulty tanks per day. This 
raises concerns that trace pharmaceuticals may be entering the ground water underlying 
these systems.
GOALS AND OBJECTIVES
This study characterizes the occurrence and estimates the concentration of 
pharmaceuticals in septic system effluent, and examines the potential for contamination 
o f shallow aquifers. It examines pharmaceutical concentrations in: (1) single family and 
community septic tanks; (2) influent and effluent o f a wastewater treatment plant; (3) 
eight ground water samples from monitoring wells in a highly productive sand and gravel 
aquifer; and (4) in a septic system and monitoring well network serving a rural high 
school. The specific study objectives were to: (1) identify target compounds; (2) develop 
sampling and analyses procedures; (3) characterize individual and community septic tank 
effluent; (4) sample ground water in a sole source aquifer that is overlain by areas 
containing sewer lines and septic systems. The data from this effort provide an inventory 
o f pharmaceuticals found in septic waste and, with limited data, examine the transport 
and fate o f pharmaceuticals in the associated ground water systems.
METHODS 
Identify target compounds of concern
Pharmaceuticals selected for this study were based on the following criteria: 1 ) 
they are commonly used drugs; 2 ) the compound has been reported to occur in the 
environment; 3) the compound ionizes well under positive electron spray mode 
(analytical consideration). Certain compounds, like ibuprofen, that fit criteria 1) and 2), 
were not included as they cannot be easily detected using the chosen analytical technique. 
Target compounds including 19 pharmaceuticals, both prescription and non-prescription
drugs, and three metabolites were selected for evaluation (Table 2, Appendix 2- 
Structures and Molecular Weights o f Pharmaceuticals).
Table 2. Pharmaceuticals analyzed. The last two columns report the maximum 
recommended dose for an adult and maximum urinary excretion percentage
C om pound Type U se
Recommended 
Dose for adult 
(mq/dav)
Maximum 
Urinary 
Excretion (%) 
(Goodman 
and Gilman, 
1990)
Acetaminophen Non-prescription drug Antipyretic 600 3 +/-1
Antipyrine
(Phenazone) Prescription A nalgesic 54 NO*
Caffeine Non-prescription drug Stimulant 210-440 1.1 +/- 0.5
Carbam azepine Prescription drug
Anticonvulsant,
antineuralgic,
antimanic,
antidepressant,
antipsychotic 100-400 <1, 3 (PDR**)
Cimetidine Prescription drug Antiasthmatic
300-800, 2-4 
times daily 62 +/- 20
C odeine Prescription drug
A nalgesic (anti­
cough)
12-60, 1-4 
times daily Negligible
Cotinine Metabolite Nicotine metabolite Metabolite ND*
Diltiazem Prescription drug Antihypertensive 30-120 <4
Erythromycin-18
Metabolite of 
Prescription drug Antibiotic 250 12 + / -7
Fenofibrate Prescription
Lipid Metabolism  
regulator 54-200 daily ND
Fluoxetine Prescription drug
Antidepressant, 
antiobsessional, and 
antibulimic
10-40 daily or 
weekly <2.5
Hydrocodone Prescription drug
A nalgesic (anti­
cough) and 
antitussive 5-7.5 ND*
Ketoprofen N on-Prescription Anti-inflammatory 25-200 <1
Metformin Prescription drug
A n tih y p erg ly cem ic 500-1000, 
twice a day ND*
Nicotine non prescription drug 4 16.7 +/- 8.6
Nifedipine Prescription drug
Antianginal (blood 
pressure control)
10-90, daily ~0
Paraxanthine (1,7- 
dimethylanthine) Metabolite Caffeine metabolite Metabolite ND*
Ranitidine Non- Prescription drug Histamine
25-300, three a 
day 69 +/- 6
Salbutamol Prescription drug
Relax restricted 
airways 2-5 ND*
Sulfam ethoxazole Prescription drug Antibiotic 200-800 14 + 1-2
Trimethoprim Prescription Drug Antibiotic 40-160 69 +/- 17
Warfarin Prescription drug Anticoagulant 1-10 <2
ND*= no data PDR**= Physicians desk reference, 2001
Field Sampling and Site Description
Five types o f sites were sampled for pharmaceuticals: 1) individual and 
community septic systems 2) the city wastewater treatment plant; 3) the Frenchtown High 
School research site; 4) shallow monitoring wells in the Missoula Aquifer, and 5) the 
Clark Fork River. A more detailed description o f each site is given below.
Thirty-two single-family and ten community septic tanks were sampled in the 
City o f Missoula (Figure 1). The single-family 3,785-L septic tanks are classified as 
STEP systems (Septic Tank Effluent Pump) and are used to collect household wastewater 
(Figure 2). When the liquid effluent reaches a volume of 2,600-L, it is pumped from the 
septic tank to the city sewer line. Solids that settle to the bottom of the tank are pumped 
out as needed. The community septic tanks, which hold 11,300 to 30,300 liters, are 
designed to catch wastewater from approximately 10-75 apartments and/or homes. These 
STEP systems discharge to the city sewer line.
Septic tank effluent samples were collected using a parastolic pump, equipped 
with new 30-cm length of silicon tubing and a section of 1.5 to 7.6-m clean polyethylene 
tubing. Samples pumped from the tanks were collected in a 2.5-L glass bottle. All 
bottles were pre-washed with methanol and Milli-Q water and dried overnight. All tubing 
used for pumping samples was new and discarded after sample collection.
The municipal wastewater treatment plant (WWTP) in Missoula, Montana is connected 
to about 57,000-population equivalents. The WWTP consists o f commonly used 
treatment steps, preliminary sedimentation followed by activated sludge treatment and 
final clarification by chlorination.
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Figure 1. Location map of the City of Missoula. Shown are sewer systems (gravity flow 
and STEP), unsewered areas, monitoring wells, the wastewater treatment plant and 
location of the surface water samples in the city of Missoula, Montana (Map Source: 
Department of Water Quality Missoula, Montana)
Sample
Manhole Cover
Liquids
Figure 2. Schematic diagram of STEP (Septic Tank Effluent Pumping) system for a single-family 
residence.
Two influent samples were obtained at the WWTP, after primary sedimentation, by 
submersing a 2.5-L glass bottle into the liquid flowing into the seeondary treatment basin. 
As an advanced wastewater treatment, Missoula WWTP uses ultraviolet treatment during 
the summer months to help destroy photoreactive compounds. Two effluent samples 
were taken before and after ultraviolet treatment. Effluent from the WWTP is then 
discharged into the Clark Fork River.
Samples of effluent from the 22,712-L septic tank of Frenchtown High School 
(350 students and staff) were collected using the same process as described for sampling 
individual STEP systems. At the high school, four shallow monitoring wells were 
sampled from a well-documented wastewater-impacted aquifer located beneath the drain 
field, and along the ground water flow path (Deborde et al. 1998; Lauerman 1999)
(Figure 3). The drain field is constructed of PVC pipe with 26 laterals buried in trenches 
0.6-m below land surface and surrounded by washed 5-cm diameter cobbles. The 
subsurface contains medium sand to a depth of 2.4 to 3.4-m, and 7.6-m of sand and 
gravel that is saturated at 1.5 to 3-m below land surface (DeBorde et al. 1998). Prior to 
sampling ground water, all 2.5-L glass bottles were silanized and clean tubing was used 
for each sample (Cras et al. 1999). Samples were obtained from wells using a parastolic 
pump and a length of new silicon and polyethylene tubing.
Eight shallow ground water wells used to monitor the water quality of the sole- 
source Missoula Aquifer were sampled to characterize the ground water near the water 
table. The Missoula aquifer is a coarse-grained gravel, unconfined aquifer that supplies 
potable water to the city and county. The aquifer varies from 15.2 to 36.6-m in thickness 
and the water table occurs between 21.3 and 30.5-m below land surface.
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Frenchtown High School
Approximate Location o f  Drainfield
Septic Tank
Direction o f  GroundwaterFlow
A- Monitoring W ells
Approximate Location of Sewage Plum(
25 m
Scale
Approximate edge 
of the drainfield
#41(11.3m)
#26
(15.3m)
#40 (6.6m) #19 (Cm)
Figure 3. Frenchtown high school septic system. Approximate location of ground 
water sewage plume located below the drainfield. Insert of ground water wells 
sampled for pharmaceutical analysis, with approximate distance from each other in 
parenthesis. Well 19 is located directly beneath the drain field (Adapted from 
Deborde et al. 1998).
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The wells were purged for more than five minutes at a rate o f approximately 10- 
L/min, to ensure that well casings were flushed. Samples were collected using disposable 
polyethylene bailers and placed in 2.5-L silanized glass bottles. One additional ground 
water sample representing potable ground water supplied by Mountain Water Company 
was obtained from the faucet o f a local home in the City of Missoula.
In an attempt to examine the concentrations o f target compounds in the Clark 
Fork River two samples were collected, one at the headwaters of the Missoula Valley and 
another downstream from the sewage treatment plant (~5.6-km) (Figure 1). Samples 
were obtained by submersing 2.5-L silanized glass bottles into the river.
All samples were transported to the lab and stored in coolers (4°C), after sample 
preparation samples were stored in lab freezers until analyzed.
Sample Preparation
At this time no standardized procedure has been adapted for sample preparation 
and analysis. I prepared samples within 1-3 days o f collection, using adjusted methods 
described by Kolpin et al. (2002) (phamj3ceutical extraction method 3). This method 
was designed to target human prescription and non-prescription drugs and their 
metabolites (Appendix 3). In brief, first a pre-filtration step was initiated by passing the 
sample through a 0.45-um glass fiber filter. Then 1-L o f sample was processed through a 
solid phase extraction (SPE) cartridge that contained 6 -cc, 500-mg of sorbant 
Hydrophilic-Lipophilic-Balance (Oasis, HLB) at a flow rate o f 15 to 25-mL/min 
(Appendix 4). Next, compounds were ext’ :.cted from the SPE cartridge using two 3-mL 
aliquots o f CH3OH and two 3-mL aliquots o f CH3OH acidified with trifluoroacetic acid 
(0.1% trifluoroacetic acid, C2HF3O2). Compounds were slowly reduced to near dryness
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under N 2 and then brought to a 1-mL solution volume with the starting mobile phase for 
the high performance liquid chromatography (HPLC) analysis, 10-mM ammonium 
formate/formic acid, (pH=3.7). All effluent samples were filtered with a 0.2-um PTFE 
syringe filter then diluted to a 10% solution, prior to analysis. Compounds were 
separated and measured by Time-of-Flight, High Performance Liquid Chromatography 
coupled with Mass Spectrometry (HPLC-TOF-MS, Waters HPLC system) in the 
laboratory of SUNY at Stony Brook, using a polar (neutral silanol) reverse-phase 
octylsilane (C8 ) HPLC column (Metasil Basic 3um, 150*2.0mm; Metachem 
Technologies). This preparation procedure was used for all samples (Benotti et al.,
2003).
Ground water sample recoveries are between 3% and 110%, depending on the 
compound (reported by personal communication with Mark Benotti o f SUNY-Stony 
Brook University) (Appendix 4). Standard curves used for quantification and calibration 
reports o f all compounds are found in Appendix 6 . For quality control one internal 
standard, '^Cs- labeled caffeine, was used (Cambridge Isotope Laboratories in 
Cambridge, Ma). Pharmaceutical standards were obtained from Aldrich and prepared by 
the personnel o f the SUNY at Stony Brook lab. Analyses were conducted in ESP+ mode 
with a selected mass range o f 100 to 800 Da. A lock mass, leucine enkephalin (Sigma 
#P9003), added post-column at a flow rate of 1-uL/min with a concentration of 5-ng/mL, 
was used to compensate for drift o f the external calibration during analysis due to 
possible temperature fluctuations and instabilities o f the power supply by a single point 
correction o f the base calibration file after analysis (Benotti et al. 2003, Ferrer and
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Thurman 2003). Quantification of compounds was estimated from the internal standard 
('^C3- labeled caffeine) injected into the sample prior to analysis.
Resultant concentrations from the above procedure must be qualified before 
discussion. This study attempted to characterize PPCP concentrations in an 
environmental compartment for which little data exist (septic tanks). Generally speaking, 
PPCPs in the septic tanks exhibited a wide range o f concentrations (from ng/L to high 
pg/L). While this offers interesting discussion, it must be noted that both the extraction 
procedure and HPLC-TOF-MS analysis was designed to study trace levels o f 
contaminants. Thus, reported concentrations, especially high values, represent a low-end 
concentration. The actual value cannot be quantitatively determined because 
phenomenon such as over-loading of SPE cartridges, ionization
suppression/enhancement, and detector saturation are likely clouding high environmental 
concentrations (Benotti et al. 2003). Although studies to qualify detector saturation and 
ionization suppression were outside the scope of this project, observation of such 
phenomenon indicate that concentrations to 500-ng/L are within the error o f the analysis. 
Systematic error increases linearly for concentrations above 500-ng/L, but considering 
the worst case, probably underestimate the highest concentrations. Therefore, values 
reported in this study should be compared to other environmental concentrations with this 
in mind.
Analytical results
As part of the method development and to maximize the resolution and sensitivity 
of the HPLC-TOF-MS, three samples were prepared at sample concentrations o f 10%, 
50% and 100% solution. The 10% solution was chosen for it produced chromatograms
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with the least amount o f matrix interference and a discernable internal standard peak. 
Thus for all effluent samples, prior to HPLC analysis, a 10% standard solution was used. 
Because standards examined during sample analysis did not produce reliable results, they 
were run again on a later date for better correlation (Appendix 6 ).
Analytical difficulty occurred during sample preparation and SPE concentration. 
Using the stated preparation methodology, target compounds were captured from a 1-L 
filtered effluent sample using a 6 -cc, 500-mg HLB sorbant. The ability for the HLB 
cartridges to capture all target compounds was evaluated by passing one sample through 
two HLB cartridges in series. Compounds such as acetaminophen, caffeine, cotinine and 
paraxathine were detected in the second processing o f 1L samples, while ketoprofen, 
nicotine and warfarin were not detected (Table 3).
Table 3. Double runs through cartridges. Samples A and B are samples from two septic 
tanks. A l and B1 are the results o f effluent processed on a HLB cartridge and A 2 and B 
2 are processed on a second HLB cartridge. All concentrations represent minimum 
concentrations.
S a m p les A cetam in op h en C affeine C otinine K etoprofen N icotine Paraxathine Warfarin
ug/L ug/L ug/L ug/L ug/L ug/L ug/L
A 1 1.09 8.26 Nd Nd Nd 67.67 1.81
A 2 0.64 1.39 0.12 Nd Nd 40.88 Nd
B 1 140.01 60.84 5.36 147.64 0.87 71.84 5.84
8 2 427.73 13.621 2.44 Nd nd 196.43 Nd
Table 4. Sample splits. These are reported by compound, total mean % comparisons, 
number of positive identified compounds parenthesis. All values compared represented 
minimum concentrations
C om pound (n=) A cetam in op h en  (9)
C affeine
(9) C arbam azepine (3) C im etid ine (2) C otin ine (8) D iltiazem  (2)
Total m ean (%) 88.4 83.2 78.1 91.7 83.9 83.2
C om pou nd  (n=) E rythrom ycin-18 (3)
C od ein e
(4) H ydrocodon e (1) K etoprofen  (1)
Metaformin
(3) N icotine (8)
Total m ean (%) 87.5 90.9 90.4 70.6 87.5 81.7
C om pou nd  (n=) Paraxathine (9)
R anitidine
(1)
S u lfam eth oxazo le
(2)
Trim ethoprim
(3) Warfarin (6)
Total m ean (%) 83.8 69.4 46.0 80.6 70.7
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Two samples were available for preparation from each site. O f all effluent 
samples, nine splits were prepared and analyzed in duplicate to determine method 
reproducibility (Table 4). All compounds exhibited reproducibility above 50% with the 
exception of sulfamethoxazole, which was only detected in two samples.
During the evaporation of the sample, solids were observed to form in the test 
tube. Visually, these samples were a dark brown color and collected on the bottom and 
sides o f the glass vial. Adding the mobile phase (10-mM ammonium formate/formic acid, 
pH=3.7) to the near dry sample re-dissolved a portion of the solid phase, but in some 
samples the solid phase remained in the vial. It is likely that the residue remaining in the 
sample vial contained target compounds. These conditions may have created analytical 
results that are lower than their actual values (Appendix 1).
Instrument detection limits and recovery data for ground water samples are 
reported for method and analysis (Personal communication with Benotti 2004) in 
Appendix 4. Recovery data for septic effluent were not completed in this study.
RESULTS
Results from the analysis o f pharmaceuticals in septic system effluent are 
presented for hoth single-family and community tanks, WWTP influent and effluent, 
Frenchtown and Missoula Valley ground water.
Single Family and Community Septic Tanks
This study analyzed for 22 pharmaceuticals in each sample. O f those; only 18 
were found above their detection limit (Figure 4).
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Figure 4. Most frequently detected compounds in raw sewage samples (community, 
single family, school septic effluent and WWTP influent). Marked (*) compounds are 
nonprescription drugs and/or there metabolites.
Concentration ranges and numbers o f occurrence are provided for all compounds 
detected in community and single-family septic tank effluent (Figure 5 and 6 )
Compounds not detected were fenofibrate, fluoxetine, nifedipine and salbutamol. 
In all community tank effluent the most detected compounds (>60%) were 
acetaminophen, caffeine, cotinine, paraxanthine and warfarin (Figure 5). In single-family 
tanks the most detected compounds (>60%) were caffeine, acetaminophen, cotinine, 
paraxanthine and warfarin (Figure 6 ).
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Figure 5. Pharmaceuticals detected in community septic tanks. Box plots report median, 
75, 25 quantities and maximum and minimum values and 0%% represent outliers. The 
numbers o f detections in samples are reported above the compound name. Two box plots 
are used to show all concentration ranges o f samples (a) higher concentrations and (b) 
lower concentrations. All concentrations represent minimum concentrations.
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Figure 6 . Pharmaceuticals detected in single-family septic tank. Box plots report median, 
75, 25 quantities and maximum and minimum values. 0%x and represent outliers and *%% 
represent extreme values. The numbers o f detections in samples are reported above the 
compound name. Two box plots are used to show all concentration ranges of samples (a) 
higher concentrations and (b) lower concentrations. All concentrations represent 
minimum concentrations.
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W astewater Treatment Plant
Comparisons o f pharmaceutical concentrations from influent and effluent sewage 
o f the city’s WWTP are reported, including concentrations o f before and after ultraviolet 
treatment (Figure 7). Acetaminophen, diltiazem, nicotine, paraxathine and warfarin were 
not detected in the outflow o f the WWTP.
□  Influent (n=3) □  Outflow before UV (n=1 ) ■  Outflow after UV (n=1 )
1000000
100000
10000
1000
100
Pharm ace uticals
Figure 7. Concentrations o f pharmaceuticals at the WWTP. Bars and boxes in the 
influent column represent a range o f three sampling period’s. Two concentrations are 
plotted o f outflow samples before and after ultraviolet treatment. All concentrations 
represent minimum concentrations.
Frenchtown High School Site
Results from the Frenchtown High School site represent two consecutive 
sampling events conducted on 10/30/03 and 11/05/03, respectively. Only twelve o f the 
twenty-two pharmaceuticals were detected in the septic tank. Pharmaceutical levels 
foimd in the school’s septic effluent had comparable concentrations between sampling
2 0
periods. The exceptions to this were erythromycin-18 and sulfamethoxazole, which 
appeared to be higher during the second sampling period (Figure 8 ).
35000
□  10.30.03 Septic Tank 
11.05.03 Septic Tank
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Figure 8 . Concentrations o f pharmaceuticals from septic effluent at Frenchtown high 
school taken on 10/30/03 and 11/05/05. Marked (*) compounds are nonprescription drugs 
and there metabolites. All concentrations represent minimum concentrations.
Ground water from four ground water wells finished below the drain field and within the 
plume of impacted ground water, tested positive for four o f the twenty-two compounds 
analyzed (Figure 9). Carbamazepine and sulfamethoxazole were the most frequently 
detected compounds in ground water at Frenchtown (Figure 9). Nicotine was positively 
detected in ground water samples but at levels below the limit o f quantification, with the 
exception o f one ground water sample (Figure 9).
2 1
a.
b.
(10/30) Frenchtown High School
o) 80
O C arbam azepine  
■  Nicotine 
□  Sulfam ethoxazole
6.6 11.3
Distance below drain field (m)
15.3
(11/05) Frenchtown High School
□  Carbamazepine
□  Sulfamethoxazole
0 6.6 11.3 15.3
Distance below drain field
Figure 9. Concentrations o f pharmaceuticals from Frenchtown high school ground water, 
taken 10/30/03(a) and 1 l/05/03(b) o f pharmaceuticals detected below drain field (0 
meters), just outside o f drain field (6 .6 m), further down the flow line (11.3m) and furthest 
away from drain field (15.3m). All concentrations represent minimum concentrations.
Missoula Valley Ground Water
Ground water samples taken in the Missoula Valley exhibited concentrations of 
pharmaceuticals in the low ng/L range (Figure 10).
2 2
o>c
N= 6 2 2 ^
C affe ine  C a r b a m a z e p in e  C otin ine  T rim ethopr im
Figure 10. Ground water box plot o f pharmaceuticals in the Missoula Valley. Box plots 
report median, 75, 25 quantities and maximum and minimum values. Oxx represent 
extreme values. All concentrations represent minimum concentrations.
Single samples of the Clark Fork River were collected at headwaters o f the 
Missoula Valley and 3.5 miles below the outfall o f the WWTP. Only two 
pharmaceuticals were above detection limit below the WWTP, caffeine at 1.37-ug/L and 
carbamazepine at 0.003-ug/L. Results from a sample o f potable ground water supplied by 
Mountain Water Company, did not show the presence o f any target compounds.
DISCUSSION
This screening level study evaluated the occurrence o f 22 pharmaceuticals in 
septic tanks, the city WWTP, along with a limited evaluation o f their persistence in 
ground water and the Clark Fork River in Missoula, Montana. These data provide unique 
information about the range o f pharmaceutical concentrations found in community and
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single-family septic tanks and effluent. Results from ground water sampling suggest that 
specific pharmaceuticals enter and persist in the subsurface.
Effluent samples
(Community, single family, school septic tanks and WWTP samples)
Non-prescription drugs
Non-prescription drugs examined in this study include acetaminophen, caffeine, 
nicotine, ranitidine, paraxanthine (caffeine metabolite), and cotinine (nicotine 
metabolite). Five o f these compounds are among the most frequently detected 
compounds in sewage for this study (Figure 4). Acetaminophen, caffeine and 
paraxanthine in community and single family tanks were detected most frequently in the 
samples, with concentrations estimated at greater then 1530-ug/L, 877-ug/L, and 910- 
ug/L, respectively (Figure 5a, 6 a). High concentrations detected in WWTP were 
estimated to be lower than septic effluent, acetaminophen at 525-ug/L, caffeine at 137- 
ug/L, and paraxanthine at 183-ug/L.
Concentrations in septic systems appear to be more variable (have a larger range) 
than samples from the WWTP. Variations in concentrations are likely the result o f the 
septic tank effluent’s susceptibility to fluctuation and/or perturbations from the people it 
serves. It is likely that W W TP’s have more stable concentrations and fluctuations are 
more subtle as it serves a diverse population and wastes are diluted.
The greater frequency o f detection and higher presumed concentrations for non­
prescription drugs compared to prescription drugs in both septic waste and WWTP 
influent, is related to their suspected greater annual use (Kolpin et al. 2002). Kolpin et al. 
(2002) observed similar findings when testing streams and rivers across the US. Their
24
work reports that non-prescription drugs were detected more frequently than other 
organic contaminants such as antibiotics, prescription drugs and reproductive hormones. 
They also frequently detected concentrations o f drug metabolites and noted the 
importance o f expanding analysis to include the possible degradates o f parent compounds 
(Kolpin et al. 2002). For example, there are more than 20 metabolites o f caffeine 
produced in the human liver (Buerge et al. 2003).
Prescription Drugs
Prescription drugs in effluent were detected less than 30% of the time, with the 
exception o f warfarin which was detected in 77% of the samples (Figure 7). The highest 
concentrations o f prescription drugs found in both single-family and community tank 
effluent were estimated to be greater than; 6.4-ug/L for carbamazepine, 1.9-ug/L for 
codeine, 0.1-ug/L for hydrocodone, 104-ug/L for ketprofen, 64-ug/L for 
sulfamethoxazole, 1.5-ug/L for trimethoprim and 23-ug/L for warfarin (Figure 5 and 6 ). 
The apparent lower concentrations and frequency of detection for prescription drugs 
could be the result o f  their limited use and accessibility. Heberer (2001a) states that a 
reliable predictor o f environmental concentrations o f pharmaceuticals is the overall 
consumption and the fate o f individual compounds in the human body. The observations 
made in this study seem to agree with this hypothesis.
In an attempt to predict the concentrations of a pharmaceutical in single-family 
septic tank effluent it was assumed that 1) no degradation occurred; 2 ) one adult in the 
household is consuming maximum dosage of each drug; 3) no drugs are being excreted in 
feces; 4) all drugs are being released at maximum urinary excretion levels as listed in 
Table 2, and 5) no drugs are reacting or degrading in the septic tank. A comparison of
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predicted septic tank concentrations to the median pharmaceutical concentrations found
in the single-family septic effluent proved to be variable (Table 5).
Table 5. Predicted and examined pharmaceutical concentrations. These represent single­
family septic tanks and assume one healthy adult is consuming each pharmaceutical.
Compound
Median concentration of compound 
in single family septic tank* (ng/L)
Estimated concentration of compound 
in septic tank* (ng/L)
Acetaminophen 206081 69230
Caffeine 79870 1292
Carbamazepine 80 1538
Cimetidine 8667 18923
Ketoprofen 104211 769
Nicotine 8710 389
Ranitidine 517 259615
Sulfamethoxazole 64767 49231
Trimethoprim 132 52923
Warfarin 6419 77
*=Assumptions
* = no degradation of compound, one 
adult is consuming drug,
* = no drugs are being excreted in solid 
phase, 2600L septic tank dilution
Predicted concentrations varied considerably from the recorded concentrations in 
single-family septic effluent. The assumption that one adult is consuming the target 
compound seems to be insufficient because concentrations found in the effluent are 
considerably higher than predicted. For example, acetaminophen, caffeine, ketoprofen, 
sulfamethoxazole and warfarin are recorded to greater than 206,080; 79,870; 64,767 and 
6,419-ng/L in the septic tank, and predicted values are 6,923, 1,292, 769, 49,231 and 77- 
ng/L (Table 5). This could be the result o f either more than one person consuming the 
drug, retention times o f aqueous septic effluent being longer than 24 hours, or direct 
disposal o f drugs into a septic tank.
Predicted concentrations of trimethoprim, ranitidine and carbamazepine are 
considerably higher than median septic effluent concentrations. This could be due to 
either the adult dosage being lower than the maximum concentration used in the
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calculation, or that some removal process (be it degradation or sorption) occurs in the 
septic tank (Table 5).
To compare the amount o f prescription drugs entering the Missoula Valley to the 
compounds reported in this study, a pharmacy in the Missoula Valley that serves 
approximately 7% o f the population estimated dosages prescribed during a 4-week period 
(Figure 11).
Dosages for 7% Missoula Population for 4 weeks
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Figure 11. Prescription drug dosages for Missoula Valley
O f the compounds analyzed for in this study, metformin, sulfamethoxazole and 
carbamazepine are the most prescribed drugs in the Missoula Valley. It was 
unanticipated that carbamazepine would be one o f the top 3 prescribed drugs based on its 
reported use in medicine (Table 1 1 ).
Wastewater treatment plant
The effluent samples at the WWTP were taken synoptically. However, 
pharmaceutical concentrations entering the plant were generally higher than levels 
leaving the plant (Figure 5). Ultraviolet treatment did not seem to significantly alter the
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apparent pharmaceutical concentrations (Figure 5). Acetaminophen, diltiazem, nicotine, 
paraxanthine and warfarin were below detection limits in WWTP outflow samples. This 
could be the result o f degradation processes by microorganisms, elimination by the 
wastewater treatment process or the stated recovery issues. Temes (1998) noted the lack 
of acetaminophen in surface water due to high removal efficiencies by W WTP’s.
Buerge et al. (2003) and Heberer et al. (2002) reported -99.3%  and 99.9% removal rates 
of WWTP for caffeine, respectively.
Missoula’s WWTP discharges water into the Clark Fork River. A single river 
water sample was taken 3.5-miles below the WWTP, contained only two 
pharmaceuticals: caffeine greater than 1.36-ug/L, and carbamazepine greater than 2.7- 
ng/L.
Hypothetical pharmaceutical concentrations down stream from the WWTP were 
determined using: 1) concentrations of compounds detected in the WWTP effluent; 2) 
discharge of the Clark Fork River in September (2003) at 1,374-million liter/day; and 3) 
discharge of the WWTP into the Clark Fork River, 28-million liter/day (Table 6 ). This 
prediction assumes that neither degradation nor retardation occurs and that no upstream 
sources of target compounds are influencing concentrations in the river. Only two of the 
nine pharmaceuticals detected in the WWTP effluent were detected downstream of the 
WWTP. This could be the result o f degradation and/or retardation, depending on the 
compound. An apparent high concentration o f caffeine detected in river water, compared 
to WWTP effluent, could be from upstream sources o f human activities, septic effluent 
influence from unsewered homes near the river or the result o f analytical uncertainty.
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Table 6 . Predicted and actual downstream from wastewater treatment plant
Compound
Outflow
(ng/L)
Predicted
Concentrations
(ng/L)
Found 3.5- 
miles 
downstream 
(ng/L)
Caffeine 615 7.0 1370
Carbamazepine 498 5.7 2.7
Cimetidine 1027 11.7 Nd
Cotinine 228 2.6 Nd
Erythromycin-18 1269 14.4 Nd
Codeine 458 5.2 Nd
Metaform in 2049 23.3 Nd
Sulfamethoxazole 297 3.4 Nd
Trimethoprim 115 1.3 Nd
nd=not detected
Ground Water
Sand and Gravel Waste Impacted Shallow Aquifer
To examine how pharmaceuticals behave in the subsurface several ground water 
wells were sampled below and near the Frenchtown High school drain field. Sampling a 
septic tank provides "‘snapshots” of concentrations moving through a septic system at a 
specific time. For example, if  someone is prescribed antibiotics for five days, while the 
drug is being consumed it will be present in the septic effluent at high concentrations. In 
an ideal wastewater system once consumption of the antibiotics and elimination from the 
body ceased, septic effluent pharmaceutical concentrations should be undetectable. 
Applying this reasoning to ground water contaminated by septic effluent, pulses o f 
antibiotics may travel through an aquifer.
The shallow aquifer below the Frenchtown High School drain field is impacted 
from septic waste as evidenced by the elevated concentrations of nitrate, chloride and 
ammonium (Lauerman 1999; Fink 2000). Only 12 o f the 22 compounds were detected in 
the school’s septic tank effluent, while only 4 of those 12 were detected in the ground
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water (Figure 9). Both carbamazepine and sulfamethoxazole have the highest recorded 
concentrations of the pharmaceuticals detected in the ground water at the high school. 
Underneath the drain field the 2-3-m thick vadose zone is eliminating approximately 65- 
75% of the pharmaceuticals detected in the school septic tank effluent. Concentrations 
of prescription drugs, carbamazepine and sulfamethoxazole may show some reduction 
after traveling through the vadose zone. This may be the result o f dilution, degradation, 
or the beginning or end o f a “pulse” o f drugs moving through the septic system.
Removal or retardation o f sulfamethoxazole in the vadose zone appears to be greater than 
carbamazepine. Concentrations o f sulfamethoxazole fell from greater than 29600-ng/L in 
the effluent to greater than 460-ng/L in the underlying ground water, a reduction of 98%. 
Carbamazepine appears to be relatively persistent in this specific subsurface environment 
of anoxic ground water (DO < 0.1-3.0-mg/L), as it is found in ground water 15.3-m down 
gradient o f the drain field (DeBorde 1998).
Carbamazepine and sulfur containing drugs are reported by previous studies to he 
more persistent in the environment. Other studies have reported the persistence of 
carbamazepine through WWTP (Temes 1998). Clara et al. (2004) examined hoth lab- 
scale and the full-scale effect o f sewage treatment plants on carbamazepine, and reported 
no significant degradation or adsorption of carbamazepine during the wastewater 
treatment processes. Heberer (2002h) reported 8 % removal rate o f carbamazepine from 
the Berlin wastewater treatment plants. Verstraeten et al. (2004) suggests anaerobic 
conditions could either aid in the persistence o f or slow down degradation of antibiotics 
in ground water. Drewes et al. (2003) reported that carbamazepine persisted through 
anoxic and aerobic conditions during travel times of up to eight years. Scheytt (2004),
30
along with other literature, states that sulfur-containing drugs, such as sulfamethoxazole 
and salphaxalazine, are relatively persistent in the environment, (Halling-Sorensen et al. 
1998; Huang et al. 2000; Hartig et al. 1999; Hartig and Jekel 2000; Lindsey et al. 2001). 
The presence o f carbamazepine and sulfamethoxazole in the Frenchtown High School 
ground water may be partially attributed to their resistance to degradation in the ground 
water system (Figure 9). This data also correlates with the high prescription rates for 
both carbamazepine and sulfamethoxazole, in the Missoula area.
The low level o f occurrence of non-prescription drugs acetaminophen, caffeine 
and other similarly structured compounds in ground water could be partially due to their 
adsorption onto the aquifer media or their degradation in the subsurface, especially if 
aerobic conditions are present (Verstraeten et al. Draft; Drewes et al. 2003). 
Concentrations for caffeine were reduced from a detectable range (18-ng/L) to 
concentrations that were below detection (BDL). Nicotine showed a similar trend. These 
shallow aquifer wells illustrate the direct impact that drain field effluent has on a shallow 
unconfined aquifer (Figure 9).
Missoula Valley Shallow Observation Wells
Shallow ground water samples of the Missoula aquifer were taken from wells 
finished near the water table (Figure 1). Ground water samples from near the water table 
(~6-15.2-m below land surface) o f the Missoula Aquifer contained five of the 22 
pharmaceuticals being investigated. O f the eight ground water wells sampled, six 
contained low levels (ng/L) o f pharmaceuticals. These included caffeine, carbamazepine, 
cotinine, nicotine and trimethoprim (Figure 12). This could be the consequence of
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impacts from septic system effluent in unsewered areas or the leakage of effluent from 
damaged sewer lines also found in some areas (Figure 12).
Large Production Drinking Water Well
High yield production wells extracting water from the eastern portion of the 
Missoula Aquifer provide potable water for a portion o f the city. These wells typically 
extract water from the base o f the aquifer. A single tap water sample obtained in 
downtown Missoula found no target compounds above the analytical detection limit. 
Ground Water Summary
Ground water was analyzed in 3 settings for PPCP’s: a shallow waste impacted 
aquifer, monitoring wells for the Missoula Aquifer and the community water supply 
system. Pharmaceuticals were only observed in the monitoring wells. The most 
persistent compounds in ground water were carbamazepine and sulfamethoxazole.
ANALYTICAL DIFFICULTIES
There are thousands o f tons o f pharmaceuticals produced and used in human and 
veterinary medicinal practices (Daughton and Jones-Lepp 2001). This can lead to 
potentially thousands o f different molecules belonging to different chemical classes, 
structures and behaviors that could re-enter the environment. It would be unrealistic and 
costly to produce analytical methods for measuring all pharmaceuticals in the 
environment. To date no single analytical procedure has been set as an accepted method 
to measure quantities o f pharmaceuticals in the environment (Castiglioni et al. 2004).
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Figure 12. Mapped pharmaceutical concentrations in the Missoula Valley.
BDL = below detection limit and BLOQ= below limit of quantification (Map source: 
Department of Water quality Missoula, Montana)
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Due to the analytical difficulties mentioned earlier, this study reports a range of 
concentrations for all raw sewage samples. Reasons for error include: 1) over saturation 
o f the 500-mg, 6-cc HLB sorbant by sewage effluent samples; 2) loss of target 
compounds during filtration 3) loss o f target compounds to the glass vial; and 4) 
concentrations of target compound over saturating the detector, causing suppression of 
ions during analysis.
Recovery data for ground water samples are reported in Appendix 5. Recovery 
data for raw sewage effluent matrix are not reported yet a limited number of recoveries 
are reported by Temes (2001). Temes (2001) reported 70% recovery of caffeine in 
sewage treatment plant effluent with other pharmaceuticals ranging from 30-142% 
recovery. Clearly, additional effort is needed to standardize analytical techniques.
FURTHER RESEARCH
The presence o f PPCP’s in our waterways and ground water is a growing concern. 
With increased sensitivity o f analytical equipment, we are able to report concentrations in 
the low ng/L range (Benotti et al. 2003). This low level o f detection also leads to 
questions about cleaning glassware and sample preparation. Methods that address sample 
preparation for raw sewage are needed. Methodology that addresses preparation and 
analysis o f samples with raw sewage matrix are in need. In addition, other compounds 
that may be important to evaluate in ground water and wastewater include; primidone, 
naproxen, gemfibrozol, and metoprolol (Scheytt 1998; Temes 1998; Drewes et al. 2003; 
Heberer 2001; Castiglioni et al. 2004). Certainly a follow up study of Missoula's ground 
water that more clearly quantifies the occurrence and concentration o f pharmaceuticals
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and personal care products should be conducted. This screening level study should be 
used to design such an effort.
CONCLUSION
Based on the analysis o f all sewage effluent samples, 18 o f the 22 compounds 
studied, were detected above the detection limit. These 18 compounds include both 
prescription and non-prescription drugs, with prescription drugs being most frequently 
detected. This is most likely the result o f greater annual use by the general population. 
Compounds most frequently detected in ground water within the waste impacted FHS 
aquifer were compounds such as carbamazepine and sulfamethoxazole. These 
compounds corresponded to pharmaceuticals prescribed in large quantities in the 
Missoula area as well as compounds known to be more persistent in the environment. 
Ground water obtained from shallow monitoring wells throughout the Missoula Valley 
contained low levels o f pharmaceuticals. Most likely these compounds are from sewage 
effluent originating from residences not connected to the city sewer and/or from leaks in 
sewer lines. The possible short- and long-term effects o f pharmaceuticals being recycled 
through the water environment are unknown.
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APPENDIX 1.
Pathways of Pharmaceutical into the Environment and Expanded Data for
Analytical Difficulties
PPCP’s can re-enter the environment through sewage disposal via excretion,
incorrect disposal o f old drugs and rinsing o f topical drugs. Depending on the compound 
in this study, pharmaceuticals can be excreted in the urine with efficiencies as high as 
62% to negligible amounts (Table 7). Table 7 reports the percent o f pharmaceuticals that 
is excreted in urine from a healthy young adult.
Table 7. Urinary excretion o f unchanged pharmaceuticals from the body
Compound
Urinary Excretion (%) 
(Goodman and Gilman 
1990) Compound
Urinary Excretion (%) 
(Goodman and Gilman 
1990)
Acetaminophen 3 +/-1 Hydrocodone Na
Antipyrine Na Ketoprofen <1
Caffeine 1.1 +/- 0.5 Metformin Na
Carbamazepine <1 Nicotine 16.7 +/- 8.6
Cimetidine 62 +/- 20 Nifedipine -0
Codeine negligible Paraxanthine Na
Cotinine Na Ranitidine 69 +/- 6
Diltiazem <4 Salbutamol Na
Diphenhydramine 1 .9 + /-0 .8 Sulfamethoxazole 14 + 1-2
Erythromycin 12 + /-7 Trimethoprim 69 +/- 17
Fenofibrate Na Warfarin <2
Fluoxetine <2.5
Na = No data
Once these pharmaceuticals leave the house they enter the municipal or septic 
tank system. These molecules can then be cleaved during sewage treatment causing the 
original pharmaceutical to be released into the environment (Heberer 2002b). 
Pharmaceuticals take several pathways to reach groundwater and surface water sources 
(Figure 1).
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Figure 13. Pathways o f pharmaceuticals into the environment (adapted from 
Heberer 2002b)
Another possible pathway for pharmaceuticals to enter the environment is through 
medicinal products for animal use, which are excreted and used as fertilizer for soil and 
can leach into groundwater or rivers and streams via run-off.
Importance of Water Resources
In the United States, ground water alone is used in % o f all American cities and 
90% of all rural households as the sole source o f drinking water. (Nizeyimana et al. 1996) 
According to Verstraeten et al. (2004), 25-30% of households use septic systems for 
wastewater disposal. In Montana, 38% of households depend on septic and cesspool 
systems for wastewater disposal (U.S. Census 2000). Within a given year it is estimated
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that -10%  of septic tanks in the United States are malfunctioning, which equals to more 
than 7000 faulty tanks per day (Knowles 1998). Leaky or malfunctioning septic tanks 
have been known to cause disease outbreaks from groundwater contamination (Scandura 
and Sobsey 1997). Past studies have focused mainly on bacteria, nitrogen and 
phosphorous as the major pollutants from leaky septic tanks or sewage disposal, but 
another suite o f bioactive chemicals such as pharmaceuticals and personal care products 
(PPCP) are receiving attention, from both human and veterinary practices.
Sample Preparation
It is also important to note that in certain samples, during preparation, after 
elution from the HLB cartridges and during evaporation under N 2 gas, a few samples 
solidified and turned a dark brown color. This dark brown solid would stick to the sides 
of the glass vial or float in solution. Adding a mobile phase to the near dry sample, re­
dissolved a portion of solid phase, but in some samples the solid phase remained on the 
glass vial. To re-dissolve all o f the solid phase from the vial, ImL o f mobile phase was 
used to re-dissolve the solidified sample (Table 8).
Table 8. Results of re-dissolving solidified samples. Sample C is first sample prepared 
using reported sample preparation; C 2 is the re-dissolved solid phase sample. All
Acetaminophen Caffeine Codeine Hydrocodone Ketoprofen Paraxathine
Sample ug/L ug/L ug/L ug/L ug/L ug/L
C 1197 1008 0.33 0.13 13 765
C 2 85 345 0.03 0.04 4 34
The recoveries from the solid phase of caffeine, ketoprofen and hydrocodone were 34, 35 
and 28%, respectively. The other pharmaceuticals, acetaminophen, codeine and 
paraxathine, were below 10% recovery.
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APPENDIX 2.
Structures and molecular weights o f pharmaceuticals
HN'
OH
Acetam inophen CgHgNO; 151.0633 
Positive Calculation using M onoisotopic weight 
152.0711 -u se s  atomic w eight o f  most abundant 
isotope o f  each element
Antipyrine C 1 1H 12N 2 O 188.0950
Pos. 189.1028
NH
Carbam azapine C 1 5 H 12N 2 O 236.0950
Pos 237.1028
HN,
' NH
N 
H
Cimetidine C |oH , 6  N&S 252.1157
Pos 253.1235
/
/
Caffeine CsH,oN4 0 2  194.0804
Pos 195.0882
Codiene C 1 8H 2 1 N O 3 299.3688
Pos 300.1599
44
Cotinine C 1 0H 12N 2 O 176.0950
Pos 177.1028
Erythrom ycin Cs-^HejNO,^ 733.4612
Pos. 734.4690
\
Diltiazem 414.1613 
Pos 415.1691
0
Fenofibrate C 2 0 H 2 1 O 4 CI 360.1128
Pos. 361.1206
H
D iphenhydram ine C 1 7H 2 1 NO  255.1623
Pos 256.1701
Fluoxetine CijHigNOF] 309.1340 
Pos. 310.1418
45
Hydrocodone C 18H 21N 03 299.3688 
Pos 300.1599
Nicotine C10H14N2 162.1157
Pos. 163.1235
OH
o
- Q
Ketoprofen C 1 6H 1 4O 3 254.0943 
Pos. 255.1021
N ifedipine C 1 7H 18N 2 O 6 346.1165 
Pos 347.1243
NH NH
■NH,
HN
0
M etformin C 4 H 11N 5 129.1014
Pos. 130.1092
Paraxanthine C 7 H 8N 4 O 2 180.0647
Pos. 181.0725
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o
MHj
Ranitidine C 1 3 H 2 2 N 4 O 3 S 314.1413
Pos. 315.1491
Trim ethoprim  C ,4 H,gN 4 0 3  290.1379
Pos 291.1457
HO
NH
HO
OH HO
Salbutamol C 1 3H 2 1 N O 3 239.1521
Pos 240.1599
W arfarin C 1 9 H 1 6 O 4 308.1049 
Pos 309.1127
Sulfam ethoxazole C 1 0H 11N 3 O 3 S 253.0521
Pos 254.0599
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APPENDIX 3
Pharmaceutical Analysis
F ilte r P rocess
1. Filter 1 L o f sam ple through 0.45-um  PTFE glass fiber filter.
a. this may require up to 15 different filters depending on the suspended solid concentration o f 
sample
2. Using SPE cartridge filter IL  through HLB cartridge (I ordered a 6cc/500m g cartridge)
a. Suction filtration apparatus through HLB cartridge (15-20m L/m in)
b. Catch container for discard o f  liquid
3. Elute twice
a. 6  mL methanol
i. 3 m L pipette pushing’s
ii. Let m ethanol gravity fall through HLB
b. 6  mL acidified methanol 0.1%  TEA in M eOH (TFA =trifluoroacetic acid)
i. 3mL pipette pushing’s
ii. Let m ethanol gravity fall through HLB
4. Reduce com pounds to near dryness under N 2 gas (immerse the sam ples in a warm water bath ~30
degrees) For Reference use lOOuL o f  M eOH in a separate test tube and stop the sam ples when
they look like the lOOuL test tube
a. This can take up to 6  hours depending on N2 stream, w ant to take hours to avoid
volatilization o f  com pounds
5. Fill test tube to Im L o f  a final volume with mobile phase (50% actonitrile and 50% formic acid 
adjusted to pH o f  3.7)
a. 890uL o f mobile phase
6 . Filter with syringe filter: for HPLC: 0.2um PTFE syringe filter
7. Dilutions o f raw sewage sam ples were run at 10% o f  concentrated sample.
a. Raw Sewage preparation: 20uL o f  concentrated sam ple + 180uL o f  mobile phase + 4uL 
o f internal standard at 5ug/mL (13-C Caffeine)
b. Ground w ater and surface water samples: 200uL o f  sam ple + 4uL o f internal standard at 
5ug/mL
H P L C - T oF  M S
Sam ple P rep  and  C a lib ra tio n
Three concentrations o f  sam ples 
100% = 200ul sample + 4ul 5ug/m L solution 13C 
50% = lOOul sample + lOOul m obil + 4 ul 13C 
10% = 20ul sam ple + 180ul m obile + 4 ul 13C
To determine the best resolution
C a lib ra tio n  (calibrate everyday) 
To s ta r t  M ach ine
(screw in line to detector)
Cap. (V) = 2600 
Sample cone = 30
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Extract cone = 5 
Desolve T = 350 
Source T = 150 
H IT  GAS BU TTON !!!!!
Put in Concentration o f  each com pound (all that you know)
Before- polyalah pos m atch the weights lOul/min 
Small amount o f  polyalah diluted with 50*50 solution 
Don’t go over 200-300 counts
Play with desolvation gas and sam ple cone to get stable sample 
M anually- 200L/hr 
Play with Cap (V) on screen until TIC is below ~300counts 
Zoom in the middle o f spectrum  
^ O p tio n s
Acquisition setup
L teff Trial = error to get peak near know weight
->Then Aquire
file name
mass 100-800 
Calibration (no select)
Run for 1 min ______________
Once all at same height hit acquire
Go to chrom atogram  then right click, and drag over chromatogram
Go to spectrum  (to calculate resolution) zoom in on 556peak (Poly al)
Choose around Lock mass -  peak m/z / 50% o f  peak 
In Chrom atogram  ->Centroid data
Process center M/z—
Resolution # calculate (ie. 6900) ® c h a rg e
Compare to iiturature values
Tools -> make calibration find re f o f  polyal (which should be created)
Select tools -> M ake calibration file
When injecting Leu before running standards 
Make sure ~30hits +- 10
1ml syringe 3ul/m in 5ug/mL leu
Once samples are run- APPLY CA LIBRA TION  FILE!
To Finish Run for dav 
Faucet button-tum  o ff 
Syringe o ff  
API gass o ff 
Temp to 100 
M ove files
- AFAM M  files- All file accurate mass measure
Quantify o ff  Afamm files (all file accurate mass m easure)
Accurate mass on every mass spectral scan under the entire chrom atogram
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U SIN G  Q U A N T IF IC A T IO N  P R O G R A M
Edit -> quantify
->M ethod editor (For 13-C Caff)
1. Quantify trace [— ] [sec] (click on — then chromatogram where peak is 198.)
2. General Parameters
a. External relative
b. P o ly ty p e -^  avg. RF (click on)
c. Point o f  origin (not force)
d. U ncheck propagate general param eters 
M ethod editor (for all com pounds standards)
1. internal re f (13 C caffeine)
2. General param eters
a. Response type (internal relative)
b. Poly type (linear)
c. Point o f  origin (include)
3. Append (not m odify)
4. Cone o f  standards
a. C o n cA  = C13
b. Cone B = Ace
c. Cone C = C aff
Save File under M ethDB
Make sure you have a colum n which lists sample type (eg. Analyte and standard)
GO to Quantify in chrom atogram  page 
Select
1. Integrate
2. Calibrate
3. Quantify
Rename curve file (where u place curve file)
C alcu la te  A ccu ra te  M ass 
Combine Spectrum under saturation for peak 
M ass M easure 
TOF
N p m ultiplier- 0.8 or 0.85 
Subtract
=actual com pound weight -  found com pound mass
=0.0022 Da
(=195.0882-195.0904)
(= -0.0022D a or 2.2 m D a (ie 4.5e-)
Tools
-elem ental com pound click on peak
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APPENDIX 4.
Instruments detection limits and % recovery for ground water samples, D ata source Benotti 2004, personal
communication.
Instrument 
detection limits 
in ng/L
* = <60%  
recovery
%
recovery
(n=8)
standard
deviation
(n=8)
relative
standard
deviation
acetam inophen 11.34 acetam inophen 110.08 6.44 5.85
antipyrine 0.27 * antipyrine 5.51 1.55 28.16
caffeine 4.26 caffeine 100.68 6.04 6.00
carbamezipine 0.47 carbamezipine 71.49 9.56 13.38
cimetidine 1.91 cimetidine 93.22 15.74 16.88
cotinine 2.71 codeine 103.31 11.83 11.45
diltiazem 0.78 cotinine 105.82 8.77 8.28
erythromycin - 1 8 2 .18 diltiazem 65.63 9.32 14.20
fenofibrate 1.59 * diphenhydramine 54.53 11.76 21.56
fluoxetine 3.87 erythromycin 3.56 2.30 64.54
ketoprofen 19.06 erythromycin - 1 8 64.18 19.39 30.21
metformin 4,38 * fenofibrate 3.26 1.76 53.96
nifedipine 5.05 * fluoxetine 56.39 13.50 23.94
paraxanthine 21.16 * hydrocodone 8.52 3.11 36.47
ranitidine 1.11 ketoprofen 83.91 15.80 18.82
salbutamol 9.60 * metformin 59.60 9,84 16.52
sulfam ethoxazole 2 .53 * nifedipine 39.89 12.75 31.96
trimethoprim 0.13 paraxanthine 102.97 6.31 6.13
warfarin 0.77 ranitidine 66.81 10.41 15.59
nicotine 4 .49 nicotine 120.03 15.54 12.94
salbutamol 108.86 10.24 9.41
* sulfam ethoxazole 37.73 3.55 9.42
* trimethoprim 12.36 3.67 29.69
* warfarin 48.71 16,43 33.73
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Calibration Report
Printed: Fri Nov 21 11:11:05 2003
Page 1 of 1
Data file: 031121eg01 - Uncalibrated 10 matches of 10 tested references
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APPENDIX 6.
Standard curves for standards run on 02/02/02 after samples which were run on 11/20/03
Compound 1: 13C-caffeine Sam ple List: 20040202a Method File: ppcp_1_caf
R esp on se  Factor: 1 ,04740
RRF SO: 0 .125148, % Relative SO: 11.9485
R esp on se  type: External Std, Area
Curve type: RF
#  Name Sam ple Text Type Std Cone RT Area R esponse ng/mL
3 040130mb04afamm 1.5 ng/m Lstd. so l’n Standard 100 9.666 94.088 94.088 89.83
4 040130mb05afamm 5.0  ng/mL std. so l’n Standard 100 9.703 99.132 99.132 94.65
5 040130m b06afam m 15 ng/mL std. sol'n Standard 100 9.684 95.396 95.396 91.08
6 040130m b07afam m 50 ng/mL std. aol'n Standard 100 9.666 104.956 104.956 100.21
7 040130m b08afam m 150 ng/mL std. sol'n Standard 100 9.703 106.746 106.746 101.91
8 040130m b09afam m 500 ng/mL std. sol'n Standard 100 9.666 128.124 128.124 122.33
Compound 6: acetam inophen Sam ple List: 20040202a Method File: ppcp_1_caf
Coefficient of Determination: 0 .999417
Calibration curve: 0 .398109  * x + 1.04441
R esponse type: Internal Std ( Ref 1 ), Area * ( IS Cone. / IS Area )
Curve type: Linear, Origin: Include, Weighting: Null, Axis trans: None
#  Name Sam ple Text Type Std Cone RT Area R esp onse ng/mL
3 040130m b04afam m 1,5 ng/mL std. sol'n Standard 1.5 7.428 1.275 1.355 0.78
4 040130m b05afam m 5.0  ng/mL std. sol'n Standard 5 7.538 4 4.035 7.51
5 040130m b06afam m 15 ng/mL std. sol'n Standard 15 7.391 6.153 6 .45 13.58
6 040130m b07afam m 50 ng/mL std. aol'n Standard 50 7.428 20.163 19.211 45.63
7 040130m b08afam m 150 ng/mL std. sol'n Standard 150 7.52 68.602 64.267 158.81
8 040130m b09afam m 500 ng/mL std. sol'n Standard 500 7.391 255 .26 199.229 497.81
Compound 7: antipyrine Sam ple List: 20040202a  Method File: ppcp_1_caf 
Coefficient of Determination: 0 .997968  
Calibration curve: 33 .2392  * x  + 141.160
R esp on se  type: Internal Std ( R ef 1 ), Area * ( IS Cone. /  IS Area )
Curve type: Linear, Origin: Include, Weighting: Null, Axis trans: None
#  Name Sam ple Text Type Std Cone RT Area R esponse ng/mL
3 040130m b04afam m 1.5 ng/m Lstd. sol'n Standard 1.5
4  040130m b05afam m 5.0  ng/mL std. sol'n Standard 5 11.922 404.761 408.305 8.04
5 040130m b06afam m 15 ng/mL std. sol'n Standard 15 11.96 673 .169 705.657 16.98
6 040130m b07afam m 50 ng/mL std. aol'n Standard 50 11.923 1867.694 1779.502 49.29
7 040130m b08afam m 150 ng/mL std. sol'n Standard 150 11.922 5470 .678 5124 .949 149.94
8 04 0 1 30m b09afam m 500 ng/mL std. sol'n Standard 500 11.941 9741.431 7603.127 224.49
Compound 8: caffeine Sam ple List: 20040202a Method File: PPcp_1_caf
Coefficient of Determination: 0 .996364
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Calibration curve: 1 .39359 * x + 5.26508
R esp on se  type: Internal Std ( Ref 1 ), Area * ( IS Cone. /  IS Area ) 
Curve type: Linear, Origin: Include, Weighting: Null, Axis trans: None
#  Name Sam ple Text Type Std Cone RT Area R espon se ng/mL
3 04 0 1 30m b04afam m 1.5 ng/mL std. sol'n Standard 1.5 9 .666 8.118 8.628 2.41
4 040130m b05afam m 5.0 ng/mL std. sol'n Standard 5 9.703 18.307 18.467 9.47
5 040130m b06afam m 15 ng/mL std. sol'n Standard 15 9.684 27 .459 28 .784 16.88
6 040130m b07afam m 50 ng/mL std. aol'n Standard 50 9.666 71.771 68.382 45.29
7 040130m b08afam m 150 ng/mL std. sol'n Standard 150 9.703 230.581 216.009 151.22
8 040130m b09afam m 500 ng/mL std. sol'n Standard 500 9.666 932.311 727.663 518.37
Compound 9: carbam azapine Sam ple List: 20040202a  Method File: ppcp_1_caf 
Coefficient of Determination: 0 .994068  
Calibration curve: 28 .6802  * x + 209 .797
R esp on se  type: Internal Std ( R ef 1 ), Area * ( IS Cone. /  IS Area )
Curve type: Linear, Origin: Include, Weighting: Null, Axis trans: None
#  Nam e Sam ple Text Type Std Cone RT Area R esponse ng/mL
3 040130m b04afam m 1.5 ng/mL std. sol'n Standard 1.5 17.077 183.424 194.949 0
4 040130m b05afam m 5.0  ng/mL std. sol'n Standard 5 17.022 467 .785 471.881 9.14
5 040130m b06afam m 15 ng/mL std. sol'n Standard 15 17.078 745.749 781.74 19.94
6 040130m b07afam m 50 ng/mL std. aol'n Standard 50 17.077 1764.309 1680.999 51.3
7 040130m b08afam m 150 ng/mL std. sol'n Standard 150 17.022 4784 .229 4481.881 148.96
8 040130m b09afam m 500 ng/mL std. sol'n Standard 500 17.059 7897 .733 6164.132 207.61
Compound 10: cimetidine Sam ple List: 20040202a Method File: ppcp_1_caf 
Coefficient of Determination: 0 .995573  
Calibration curve: 3 .27345  * x + 20 .7305
R esp on se  type: Internal Std ( R ef 1 ), Area * ( IS Cone. / IS Area )
Curve type: Linear, Origin: Include, Weighting: Null, Axis trans: None
#  Name Sam ple Text Type Std Cone RT Area R esponse ng/mL
3 040130m b04afam m 1.5 ng/mL std. sol'n Standard 1.5 7.63 18.322 19.473 0
4  040130m b05afam m 5.0 ng/mL std. sol'n Standard 5 7.722 48 .988 49.417 8.76
5 040130m b06afam m 15 ng/mL std. sol'n Standard 15 7.612 77.685 81.434 18.54
6 040130m b07afam m 50 ng/mL std. aol'n Standard 50 7.63 200.604 191.132 52.06
7 040130m b08afam m 150 ng/mL std. sol'n Standard 150 7.703 542.265 507.996 148.85
8 040130m b09afam m 500 ng/mL std. sol'n Standard 500 7.63 1435.299 1120.242 335.89
Compound 11: cotinine Sam ple List: 20040202a Method File: ppcp_1_caf 
Coefficient of Determination: 0 .998948  
Calibration curve: 8.88401 * x + 27 .6540
R esp on se  type: Internal Std ( R ef 1 ), Area * ( IS Cone. / IS Area )
Curve type: Linear, Origin: Include, Weighting: Null, Axis trans: None
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#  Name Sam ple Text Type Std Cone RT Area R esp on se ng/mL
3 040130m  b04 afa m m 1.5 ng/mL std. sol'n Standard 1.5 5.851 32 .418 34.455 0.77
4 040130m b05afamm 5.0 ng/mL std. sol'n Standard 5 5.832 90 .286 91.077 7.14
5 040130mb06afamm 15 ng/mL std. sol'n Standard 15 5.832 151.856 159.185 14.81
6 0 4 0 1 30mb07afamm 50 ng/mL std. aol'n Standard 50 5.832 429 .579 409 .294 42 .96
7 040130mb08afamm 150 ng/mL std. sol'n Standard 150 5.851 1563.841 1465.011 161.79
8 040130m b09afam m 500 ng/mL std. sol'n Standard 500 5.851 5694 .307 4444.372 497.15
Compound 12: diltiazem Sam ple List: 20040202a Mettiod File: ppcp_1_caf 
Coefficient of Determination: 0 .993240  
Calibration curve: 38 .8243  * x + 296 .030
R esponse type: Internal Std ( R ef 1 ), Area * ( IS Cone. /  IS Area )
Curve type: Linear, Origin; Include, Weighting: Null, Axis trans: None
#  Name Sam ple Text Type Std Cone RT Area R esp on se ng/mL
3 040130m b04afam m 1.5 ng/m Lstd. sol'n Standard 1.5 16.655 256 .773 272.907 0
4 040130m b05afam m 5.0 ng/mL std. sol'n Standard 5 16.619 612.121 617.481 8.28
5 040130m b06afam m 15 ng/mL std. sol'n Standard 15 16.674 965.565 1012.165 18.45
6 040130m b07afam m 50 ng/mL std. aol'n Standard 50 16.692 2557 .658 2436 .886 55.14
7 040130m b08afam m 150 ng/mL std. sol'n Standard 150 16.637 6443 .525 6036.315 147.85
8 040130m b09afam m 500 ng/mL std. sol'n Standard 500 16.674 10146.1 7918.972 196.34
Compound 13: erythromycin-18 Sam ple List: 20040202a Method File: ppcp_1_caf 
Coefficient of Determination: 0 .988260  
Calibration curve: 2 .00115  * x + 34 .5099
R esponse type: Internal Std ( R ef 1 ), Area * ( IS Cone. /  IS Area )
Curve type: Linear, Origin: Include, Weighting: Null, Axis trans: None
#  Name Sam ple Text Type Std Cone RT Area R espon se ng/mL
3 040130m b04afam m 1.5 ng/mL std. sol'n Standard 1.5 17.132 14.851 15.784 0
4 040130m b05afam m 5.0  ng/mL std. sol'n Standard 5 17,206 35.222 35.53 0.51
5 040130m b06afam m 15 ng/mL std. sol'n Standard 15 17.132 56.133 58.842 12.16
6 040130m b07afam m 50 ng/mL std. aol'n Standard 50 17.169 155.663 148.313 56.87
7 040130m b08afam m 150 ng/mL std. sol'n Standard 150 17.224 446 .029 417.841 191.56
8 040130m b09afam m 500 ng/mL std. sol'n Standard 500 17.242 1292.884 1009.088 487.01
Compound 14: fenofibrate Sam ple List: 20040202a Method File: ppcp_1_caf 
Coefficient of Detemnination: 0 .991857  
Calibration curve: 7 .44159  * x + 112.478
R esp on se  type: Internal Std ( R ef 1 ), Area * ( IS Cone. / IS Area )
Curve type: Linear, Origin: Include, Weighting: Null, Axis trans: None
#  Name
3 040130m b04afam m
4 040130m b05afam m
5 04 0 1 30m b06afam m
Sam ple Text Type Std Cone RT Area R esp on se  ng/mL
1.5 ng/mL std. sol'n Standard 1.5 29 .313  35 .188  37 .399  0
5.0  ng/mL std. sol'n Standard 5 29 .35  107.759  108.703 0
15 ng/m Lstd. sol'n Standard 15 29 .277  171.117 179.375 8.99
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6 04 0 1 30m b07afam m
7 040130m b08afam m
8 040130m b09afam m
50 ng/mL std. aol'n Standard 
150 ng/mL std sol'n Standard
500 ng/mL std. sol'n Standard
50 29.331 751 .419  715 .937  81.09
150 29 .368  1424 .723  1334 685 164.24
500 29 .35  4 8 4 3 .545  3780 .357  492 .89
Compound 15: fluoxetine Sam ple List: 20040202a Mettiod File: ppcp_1_caf
Coefficient of Determination: 0 .988688
Calibration curve: 2 .30158  * x + 22.7278
R esp on se  type: Internal Std ( R ef 1 ), Area * ( IS Cone. / IS Area )
Curve type: Linear, Origin: Include, Welgtiting: Null, Axis trans: None
#  Name Sam ple Text Type Std Cone RT Area R esp on se ng/mL
3 040130m b04afamm 1.5 ng/mL std. sol'n Standard 1.5 18.747 18.138 19.278 0
4 040130m b05afam m 5.0 ng/mL std. sol'n Standard 5 18.728 44.151 44 .538 9.48
5 040130m b06afamm 15 ng/mL std. sol'n Standard 15 18.783 65.432 68.59 19.93
6 040130m b07afam m 50 ng/mL std. aol'n Standard 50 18.802 159.433 151.905 56.13
7 040130mb08afamm 150 ng/mL std. sol'n Standard 150 18.747 386.269 361.858 147.35
8 040130m b09afam m 500 ng/mL std. sol'n Standard 500 18.802 838.408 654.372 274.44
Compound 16: ketoprofen Sam ple List: 20040202a Mettiod File: ppcp_1_caf
Coefficient of Determination: 0 .995968
Calibration curve: 0 .409053  * x + 0 .471100
R esp on se  type: Internal Std ( Ref 1 ), Area * ( IS Cone. / IS Area )
Curve type: Linear, Origin: Include, Welgtiting: Null, Axis trans: None
#  Name Sam ple Text Type Std Cone RT Area R esponse ng/mL
3 040130m b04afam m 1,5 ng/mL std. sol'n Standard 1.5 19.939 1.112 1.182 1.74
4 040130m b05afam m 5.0  ng/mL std. sol'n Standard 5 19.847 4 .069 4 .105 8.88
5 040130m b06afam m 15 ng/mL std. sol'n Standard 15 19.921 7.023 7.362 16.85
6 040130m b07afam m 50 ng/mL std aol'n Standard 50 19.939 19.064 18.164 43.25
7 040130m b08afam m 150 ng/mL std. sol'n Standard 150 19.847 66 .844 62.62 151.93
8 040130m b09afam m 500 ng/mL std. sol'n Standard 500 19.921 292.119 227.997 556.23
Compound 17: metformin Sam ple List: 20040202a  Mettiod File: ppcp_1_caf 
Coefficient of Determination: 0 .998085  
Calibration curve: 1 .24376 * x + 1.60357
R esp on se  type: Internal Std ( R ef 1 ), Area * ( IS Cone. /  IS Area )
Curve type: Linear, Origin: Include, Welgtiting: Null, /Vxis trans: None
#  Name Sam ple Text Type Std Cone RT Area R esp on se ng/mL
3 0 4 0 1 30m b04afam m 1.5 ng/mL std. sol'n Standard 1.5 1.925 4 .455 4 .735 2.52
4 0 4 0 1 30m b05afam m 5.0 ng/mL std. sol'n Standard 5 1.943 10.539 10.631 7.26
5 0 4 0 1 30m b06afam m 15 ng/mL std. sol'n Standard 15 1.925 20 .892 21.9 16.32
6 0 4 0 1 30m b07afam m 50 ng/mL std. aol'n Standard 50 1.943 60 .906 58.03 45.37
7 0 4 0 1 30m b08afam m 150 ng/mL std. sol'n Standard 150 1.943 202 .623 189.818 151.33
8 04 0 1 30m b09afam m 500 ng/mL std. sol'n Standard 500 1.943 360.462 281 .338 224.91
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Compound 18: nicotine Sam ple List: 20040202a  Method File: ppcp_1_caf 
Coefficient of Detemnination: 0 .974948  
Calibration curve: 1 .35489 * x + -6 .53392
R esp on se  type: Internal Std ( R ef 1 ), Area * ( IS Cone. /  IS Area )
Curve type: Linear, Origin: Include, Weighting: Null, Axis trans: None
#  Name Sam ple Text Type Std Cone RT Area R esp onse ng/mL
3 040130m b04afam m 1.5 ng/mL std. sol'n Standard 1.5 3.337 0 .63 0.67 5.32
4 040130m b05afam m 5.0  ng/mL std. sol'n Standard 5 3.337 3.506 3.537 7.43
5 040130m b06afam m 15 ng/mL std. sol'n Standard 15 3.282 15.487 16.234 16.8
6 040130m b07afam m 50 ng/mL std. aol'n Standard 50 3.301 37 .417 35.65 31.13
7 040130m b08afam m 150 ng/mL std. sol'n Standard 150 3.337 218 .63 204.813 155.99
8 040130m b09afam m 500 ng/mL std. sol'n Standard 500 3.264 1100.906 859.25 639.01
Compound 19: nifedipine Sam ple List: 20040202a Method File: ppcp_1_caf 
Coefficient of Determination: 0 .989167  
Calibration curve: 1 .20130 * x + 11.0205
R esp on se  type: Internal Std ( Ref 1 ), Area * ( IS Cone. /  IS Area )
Curve type: Linear, Origin: Include, Weighting: Null, Axis trans: None
#  Name Sam ple Text Type Std Cone RT Area R espon se ng/mL
3 040130m b04afam m 1.5 ng/mL std. sol'n Standard 1.5 20.544 8.394 8.921 0
4 040130m b05afam m 5.0  ng/mL std. sol'n Standard 5 20.471 20.146 20.322 7.74
5 040130m b06afam m 15 ng/mL std. sol'n Standard 15 20.544 34.835 36.516 21.22
6 040130m b07afam m 50 ng/mL std. aol'n Standard 50 20.563 82.431 78.539 56.2
7 040130m b08afam m 150 ng/mL std. sol'n Standard 150 20.452 200 .59 187.913 147.25
8 040130m b09afam m 500 ng/mL std. sol'n Standard 500 20.545 436 .994 341.071 274.74
Compound 20: paraxanthine Sam ple List: 20040202a Method File: ppcp_1_caf
Coefficient of Determination: 0 .992360
Calibration curve: 0 .122040  * x + 1.32657
R esp on se  type: Internal Std ( R ef 1 ), Area * ( IS Cone. / IS Area )
Curve type: Linear, Origin: Include, Weighting: Null, Axis trans: None
#  Name Sam ple Text Type Std Cone RT Area R esp on se ng/mL
3 040130m b04afam m 1.5 ng/mL std. sol'n Standard 1.5 8 .089 0.349 0.371 0
4 040130m b05afam m 5.0 ng/mL std. sol'n Standard 5 8.162 1.607 1 621 2.41
5 040130m b06afam m 15 ng/mL std. sol'n Standard 15 8.089 2.932 3.074 14.31
6 040130m b07afam m 50 ng/mL std. aol'n Standard 50 8.089 7.638 7.277 48.76
7 040130m b08afam m 150 ng/mL std. sol'n Standard 150 8.144 25.519 23 .906 185.02
8 040130m b09afam m 500 ng/mL std. sol'n Standard 500 8.07 78 .269 61 .088 489.69
Compound 6: ranitidine Sam ple List: 20040202b  Method File: ppcp_2_caf 
Coefficient of Determination: 0 .997248  
Calibration curve: 12 .0738 * x + 54 .1978
R esp on se  type: Internal Std ( R ef 1 ), Area * ( IS Cone. / IS Area )
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Curve type: Linear, Origin: Include, Weighting: Null, Axis trans: None
#  Name Sam ple Text Type Std Cone RT Area R esp on se ng/mL
3 040130mb04afamm 1.5 ng/mL std. sol'n Standard 1.5 8.107 53.803 57.396 0.26
4 040130mb05afamm 5.0 ng/mL std. sol'n Standard 5 8.18 167.097 168.949 9.5
5 04 0 1 30mb06afamm 15 ng/mL std. sol'n Standard 15 8.107 249 .623 260.842 17.12
6 040130mb07afamm 50 ng/mL std. aol'n Standard 50 8.125 680 .473 648.002 49.18
7 0 4 0 1 30mb08afamm 150 ng/mL std. sol'n Standard 150 8.162 1985.344 1864.348 149.92
8 040130m b09afam m 500 ng/mL std. sol'n Standard 500 8.125 4944 .368 3854.356 314.74
Compound 7: salbutamol Sam ple List: 20040202b  Method File: ppcp_2_caf
Coefficient of Determination: 0 .997604
Calibration curve: 0 .734530  * x + 1.87635
R esponse type: Internal Std ( Ref 1 ), Area * ( IS Cone. / IS Area )
Curve type: Linear, Origin: Include, Weighting: Null, Axis trans: None
#  Name Sam ple Text Type Std Cone RT Area R esponse ng/mL
3 0 4 0 1 30m b04afam m 1.5 ng/mL std. sol'n Standard 1.5 7.08 2.944 3.141 1.72
4 040130m b05afam m 5.0 ng/mL std. sol'n Standard 5 7.19 8.627 8.723 9.32
5 040130m b06afam m 15 ng/mL std. sol'n Standard 15 7.08 12.861 13.439 15.74
6 040130m b07afam m 50 ng/mL std. aol'n Standard 50 7.098 37.635 35.839 46.24
7 040130m b08afam m 150 ng/mL std. sol'n Standard 150 7.171 120.137 112.815 151.03
8 040130mb09afamm 500 ng/mL std. sol'n Standard 500 7.098 326.807 254.761 344.28
Compound 8: sulfam ethoxazole Sam ple List: 20040202b  Method File: ppcp_2_caf 
Coefficient of Determination: 0.986111  
Calibration curve: 2 .34738  * x + 55 .8413
R esp on se  type: Internal Std ( Ref 1 ), Area * ( IS Cone. /  IS Area )
Curve type: Linear, Origin: Include, Weighting: Null, Axis trans: None
#  Name Sam ple Text Type Std Cone RT Area R esponse ng/mL
3 040130m b04afam m 1.5 ng/mL std. sol'n Standard 1.5 14.564 27.511 29.348 0
4  040130m b05afam m 5.0 ng/mL std. sol'n Standard 5 14.527 62 .063 62.751 2.94
5 040130m b06afam m 15 ng/mL std. sol'n Standard 15 14.693 91.566 95.681 16.97
6 040130m b07afam m 50 ng/mL std. aol'n Standard 50 14.546 199.76 190.228 57.25
7 040130m b08afam m 150 ng/mL std. sol'n Standard 150 14.509 542.038 509.004 193.05
8 040130m b09afam m 500 ng/mL std. sol'n Standard 500 14.509 1536.17 1197.513 486.36
Compound 9: trimethoprim Sam ple List: 20040202b  Method File: ppcp_2_caf 
Coefficient of Determination: 0 .989710  
Calibration curve: 23.1741 * x + 227 .928
R esp on se  type: Internal Std ( R ef 1 ), Area * { IS Cone. /  IS Area )
Curve type: Linear, Origin: Include, Weighting: Null, Axis trans: None
#  Nam e
3 04 0 1 30m b04afam m
4 040130m b05afam m
5 040130m b06afam m
6 04 0 1 30m b07afam m
Sam ple Text Type Std C one RT Area R esp on se  ng/mL
1.5 ng/m Lstd. sol'n Standard 1.5 10.803 195.744  208 .816  0
5.0 ng/mL std. sol'n Standard 5 10.822 439 .798  444 .672  9.35
15 ng/m Lstd. sol'n Standard 15 10.859 663 .629  693 .454  20.09
50 ng/mL std. aol'n Standard 50 10.822 1578.395 1503.076 55.02
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7 040130m b08afam m
8 0 4 0 1 30mb09afamm
150 ng/mL std. so l’n Standard
500 ng/mL std. sol'n Standard
150 10.822 3887 .545  3650.62 147.69
500 10.822 6245 .866  4868 .932  200.27
Compound 10: warfarin Sam ple List: 20040202b  Method File: ppcp_2_caf 
Coefficient of Determination: 0 .979874  
Calibration curve: 10.3899 * x + 121.351
R esp on se  type: Internal Std ( R ef 1 ), Area * ( IS Cone. /  IS Area )
Curve type: Linear, Origin: Include, Weighting: Null, /kxis trans: None
#  Name Sam ple Text Type Std Cone RT Area R esponse ng/mL
3 040130m b04afam m 1.5 ng/mL std. sol'n Standard 1.5 21 .48 85.54 91.252 0
4 040130m b05afam m 5.0 ng/mL std. sol'n Standard 5 21 .388 203 .37 205.624 8.11
5 040130m b06afam m 15 ng/mL std. sol'n Standard 15 21.462 325.635 340.27 21.07
6 040130m b07afam m 50 ng/mL std. aol'n Standard 50 21.48 796 .72 758.701 61.34
7 040130m b08afam m 150 ng/mL std. sol'n Standard 150 21.37 1739.654 1633.631 145.55
8 040130m b09afam m 500 ng/mL std. sol'n Standard 500 21.48 4353 .2 3393.514 314.94
Compound 11: codeine Sam ple List: 20040202b  Method File: ppcp_2_caf
Coefficient of Determination: 0 .994776
Calibration curve: 15 .7700 * x + 86 .1003
R esponse type: Internal Std ( R ef 1 ), Area * ( IS Cone. /  IS Area )
Curve type: Linear, Origin: Include, Weighting: Null, Axis trans: None
#  Name Sam ple Text Type Std Cone RT Area R esp on se ng/mL
3 040130m b04afam m 1.5 ng/mL std. sol'n Standard 1.5 9.226 108.286 115.517 1.87
4 040130m b05afam m 5.0 ng/mL std. sol'n Standard 5 9.263 238.535 241.178 9.83
5 040130m b06afam m 15 ng/mL std. sol'n Standard 15 9.245 366.744 383.227 18.84
6 040130m b07afam m 50 ng/mL std. aol'n Standard 50 9.245 843 .118 802.885 45.45
7 040130m b08afam m 150 ng/mL std. sol'n Standard 150 9.262 2626 .948 2466.849 150.97
8 040130m b09afam m 500 ng/mL std. sol'n Standard 500 9.245 5520 .744 4303 .667 267.44
Compound 12: hydrocodone Sam ple List: 20040202b  Method File: ppcp_2_caf 
Coefficient of Determination: 0 .997200  
Calibration curve: 22 .2776  * x + 87 .0299
R esp on se  type: Internal Std ( R ef 1 ), Area * ( IS Cone. /  IS Area )
Curve type: Linear, Origin: Include, Weighting: Null, Axis trans: None
#  Name Sam ple Text Type Std Cone RT Area R esponse ng/mL
3 040130m b04afam m 1.5 ng/mL std. sol'n Standard 1.5 10.583 106.315 113.415 1.18
4 040130m b05afam m 5.0 ng/mL std. sol'n Standard 5 10.602 287.355 290.539 9.14
5 040130m b06afam m 15 ng/mL std. sol'n Standard 15 10.639 455.72 476.201 17.47
6 040130m b07afam m 50 ng/mL std. aol'n Standard 50 10.602 1190.884 1134.056 47
7 040130m b08afam m 150 ng/mL std. sol'n Standard 150 10.602 3665.86 3442.445 150.62
8 040130m b09afam m 500 ng/mL std. sol'n Standard 500 10.602 7312 .643 5700.532 251.98
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APPENDIX 7.
Department of water quality Missoula Valley wells sampled for pharmaceuticals.
WATER QUALITY DISTRICT
Monitoring Well Network
(revised 10/99)
WQD ID LEGAL ID PHYSICAL LOCATION TOTAL DEPTH SCREEN INTERVAL Latitude Longitude x-coordlnates y-coordlnates
(Feet) (Feet)
WQD-1 W152129A Touchette Ln., Frenchtown 22.7 5-25 47 01 50.705 -114 16 17.906 237668.1666 320027.6417
WQD-5 W131919C Hawthorne School 35.45 10-35 46 51 58.428 -114 03 01.094 253391.5562 300779.6998
WQD-6 W131931D Larchmont (shallow) 50 02 32-52 46 5016.687 -114 02 32.972 253803.8004 297610.5784
WQD-7 W132026D Humble / Mount 25.96 5-25 46 51 21.469 -114 05 26.724 250247.4055 299820.8464
WQD-8 W131930D O.S. Porter School 53 76 35-55 46 51 02.617 -114 02 20.539 254148.7777 299010.4061
WQD-11 W131914C Alvina Park 24 4-24 46 52 46 774 -113 58 27.737 259253.3796 301936.1411
WQD-33 U132025D Tower Street (DSL) (MV-40) 50.38 38-48 46 51 23.391 -114 03 34.546 252621.7552 299741.3966
WOD-36 W132026B Spurgln/Kellv Island 28.5 8 5-28.5 46 51 38.6 -114 05 57.1 249644 6561 300386 351
o
A PPENDIX 8.
Pharmaceutical concentrations from septic tank effluent, adjusted for dilution
M asslynx N am e Type of S am ple D ate and  sam ple  ID A cetam inophen Antipyrine C affiene C arb a m aze p in e
nq/L nq/L nq/L nq/L
0 3 1 1 17eg04afam m Com m unity Tank 06  17 03  1a 42261 30875
031117  eqO Safam  m Com m unity Tank 06  17 03 1b 42063 14559
0 3 1 1 17eg06afam m Com m unity Tank 06  17 03 2 a 28562 19862
0 3 1 1 17eq07afam m Com m unity Tank 06 17 03 2b 23440 17382
0 3 1 1 17eq08afam m Com m unity Tank 06 17 03  3 a 19478 30234
0 3 1 1 1 7eq09afam m Com m unity Tank 06 17 03  3b 14908 40015
0 3 1 117eq10afam m Com m unity Tank 06  17 03  4a 16772 27659 1448
0 3 1 1 17eq1 la fam m Com m unity Tank 06  17 03 4b 12351 25602 808
0 3 1 1 17eg12afam m Com m unity Tank 06 17 03 6 a 463344 456626
0 3 1 1 17eg13afam m C om m unity Tank 06 17 03 6b 385010 344824
0 3 1 1 17eg14afam m Com m unity Tank 06 17 03  8a 970639 388941
0 31117eq15a fam m Com m unity Tank 06 17 03 8b (Spiked 5000ug/m L) 1243706 579460 28628
0 31117eq16a fam m Com m unity Tank 06 17 03 9a 365530 508898
0 31117eq17a fam m Com m unity Tank 06 17 03 9b (sp iked  Im L 5000uq/m L) 793214 946714 48488
03 1 1 1 8 eq  10afam  m Com m unity Tank 06 17 10a 400741 414130
0311 IS a g l  la fam m Single H om e Tank 07 01 l a 4596147 50291
0 31118eg12a fam m Single H om e T ank 07 01 2a 1322401 877587
0 3 1 1 18eq13afam m Single H om e T ank 07 01 2b (lots stuck on vial) 1196897 1007822
03 1 1 1 8eq14afam m Single H om e T ank 07 01 2b2 (890uL of m obile p h a s e  to redis 84960 345019
0 31118eq15a fam m Single H om e T ank 07 01 3a 4871 18210
0 3 1 1 18eg16afam m Single H om e T ank 07 01 4a 1310272 508944
0 3 1 1 18eg17afam m Single H om e T ank 07 01 5a 55283 16305 6
0 3 1 118eq18afam m Single H om e Tank 07 01 6a 2959 239614
0 3 1 1 18eg19afam m Single H om e T ank 07 01 7a 71302
0 3 1 1 18eg20afam m Single H om e T ank 07 01 8a 161708 349382
0 3 1 118eg21 afam m Single H om e T ank 07 01 9a 1269618 1834 172985
0 3 1 1 1 8eq22a fam m Single H om e T ank 07 01 10a 5486 17849
0 3 1 1 1 8eq23a fam m Single H om e T ank 07 16 l a 21864 8559
0 3 1 1 1 8eg24a fam m Single H om e Tank 07 16 2a 902979 463198
0 31118eg25a fam m Single H om e Tank 07 16 3a 41751 52955
0 3 1 1 1 8eq26a fam m Single H om e Tank 07 16 4 a 46479 7854 80970
0 3 1 1 1 9eg04afam m A Single H om e Tank 07 16 5a 516654 138970
0 3 1 1 1 9eq05afam m Single H om e Tank 07 16 6a 30696 70514
0 3 1 1 1 9eg06afam m Single H om e Tank 07 16 7a 408090 78770
0 3 1 1 1 9eg08afam m Single H om e Tank 07 16 9a 15399 17750
0 3 1 1 1 9eq09afam m Single H om e Tank 07 16 10a 206081 157670
0 3 1 1 19eg10afam m Single H om e Tank 07 16 11a 471217 407085
0 3 1 1 19eq1 la fam m Single H om e Tank 07 16 12a 424720 410212
0 3 1 1 19eq12afam m Single H om e Tank 07 16 13a 1530156 87613
03111 9 eg 1 3 a fam m Single H om e Tank 07 16 14a 41567 5855 231
03111 9 eq 1 4 a fam m Single H om e Tank 07 16 15a 738053 668556
03111 9 eq 1 5 a fam m Single H om e Tank 09  02 l a 2692358 338233
0 3 1 1 19eg16afam m Single H om e Tank 09  02 2a 233221 30809
0 3 1 1 19eq18afam m Single H om e Tank 09  02 4a 1409801 436467
0 3 1 1 19eq19afam m Single H om e Tank 09  02 5a 75796
03111 9 eq 2 0 a fam m Inflow 09  30  1 525079 137607 486
03111 9 ep 2 1 a fam m Outflow befo re  ultraviolet trea tm en t 09  30  2 719 470
03111 9 eq 2 2 a fam m Outflow after ultraviolet trea tm en t 09  30  3 616 498
0 3 1 120eq04afam m Single H om e Tank 09  02 3a 422328
031121 eq04afam m Single H om e Tank 09  02 8b 1086 8255
031121 eqO Safam  m Single H om e Tank 09 02 0b2 (two runs through HLB) 639 1395
0 3112 1 eg 0 7 a fam m non-silinized G lassw are  wwtp 1 0 2 7  l a 261582 109136 175
0 3 1 121eq08afam m non- silinized G lassw are  wwtp 10 27 1b 257830 103151 205
0 3112 1 eq 0 9 a fam m Silinized G lassw are  w w \p 10 27 2a 296188 87584 200
03112 1 eg 1 0 a fam m silinized g la ssw are  wwtp 10 27  2b 291914 87071 215
031121eq15a fam m F renchtow n High school 10 30  1 30998 53684 454
031121 eq20afam m Frenchtow n High school 11 05  1 25814 62192 262
031121 eq27a fam  m Single H om e Tank 9 02 2b 148151 22667
0 31121eq28a fam m Single H om e Tank 09  02  10a 130392 54581
0 31121eq29a fam m Single H om e Tank 09  02  10b 140017 60844
03112 1 eq 3 0 a fam m Single H om e Tank 09  02  10b2 (two runs through HLB) 427739 13621
030723m b08afam m Single H om e Tank 07 01 03  3b  10% 10717 21170
030723m b09afam m Single H om e Tank 07 01 03  3b  50% 24370 35253
030723m b1 Oafamm Single H om e Tank 07 01 03  3b  100% 13678 19124
030724m  b03afam  m Single H om e Tank 6 .17 .03 -5a 144993 63263
0 3 0 724m b04afam m Single H om e Tank 6 .17 .03-5b  (spiked) 533558 278121 23511
0 3 0 724m b08afam m Single H om e Tank 6 .l7 .0 3 -7 a 230808 418338 726
030724m  b09afam m Single H om e Tank 6 .17  03-7b  spiked 708103 621381 33668
0 3 1 121eq04afam m Single H om e Tank 09  02 8b 1086 8255
0 3 1 121eq05afam m Single H om e Tank 09 02 8b2 (two runs th rough HLB) 639 1395
Blanks = BDL
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APPFNDIX 8 (continued).
Pharmaceutical concentrations from septic tank effluent, adjusted for dilution
M asslvnx Name Type of Sam ple Date and sample ID Cimetidine Cotinine Diltiazem Erythromycin-18 Codiene
nq/L ng/L ng/L ng/L ng/L
031 n 7 eq 0 4 afam m Community Tank 06 17 03 1a 2238
031 1 17efl05afamm Community Tank 06 17 03 1b 2793
031117ea06afam m Community Tank 06 17 03 2a 2866 1107
031 1 17ea07afam m Community Tank 06 17 03 2b 2366 1284
031117ea08afam m Community Tank 06 17 03 3a 713 2838 398
0 31117eo09afam m Community Tank 06 17 03 3b 3825 5
0 31117eq10afam m Community Tank 06 17 03 4a 3377
031117eo11afam m Community Tank 06 17 03 4b 2781
031117ea12afam m Community Tank 06 17 03 6a 28763 1384
031 1 17eg13afam m Community Tank 06 17 03 6b 18973 1127
031 1 17eg14afam m Community Tank 06 17 03 8a 38276
031117eg15afam m Community Tank 06 17 03 8b (Spiked 5000uq/mL) 32204 5159
031117eg16afam m Community Tank 06 17 03 9a 662
031117eq17afam m Community Tank 06 17 03 9b (spiked ImL SOOOuq/mL) 1139
031116eq10afam m Community Tank 06 17 10a 3260
031118eg11afam m Single Home Tank 07 01 la
031118eq12afam m Single Home Tank 07 01 2a 277
031118eq13afam m Single Home Tank 07 01 2b (lots stuck on vial) 329
0 31 1 18eq14afam m Single Home Tank 07 01 2b2 (890uL of mobile p hase  to redissolve) 26
0 31 1 18eq15afam m Single Home Tank 07 01 3a 318
0 31116eq16afam m Single Home Tank 07 01 4a 67470 1958
031118eq17afam m Single Home Tank 07 01 5a
031118eq18afam m Single Home Tank 07 01 6a 258
031118eq19afam m Single Home Tank 07 01 7a
031118eq20afam m Single Home Tank 07 01 8a 4181 246
031118eg21afam m Single Home Tank 07 01 9a 370 5
031118eq22afam m Single Home Tank 07 01 10a 103
031118eq23afam m Single Home Tank 07 16 la 2952
031118eq24afam m Single Home Tank 07 16 2a 80642
0 31118eq25afam m Single Home Tank 07 16 3a 151079 262
031118eg26afam m Single Home Tank 07 16 4a 101029 291
0 31 1 19eq04afammA Single Home Tank 07 16 5a 59170
0 3 1 119eg05afam m Single Home Tank 07 16 6a 8915
0 31 1 19eq06afam m Single Home Tank 07 16 7a 309821
0 31 1 19eq06afam m Single Home Tank 07 16 9a
0 311l9eq09afam m Single Home Tank 07 16 10a 6507
0 31119eq10afam m Single Home Tank 07 16 11a 4733
0 31119eq1 lafam m Single Home Tank 07 16 12a 2735
031119eq12afam m Single Home Tank 07 16 13a 62782
0 31 1 19eq13afam m Single Home Tank 07 16 14a 1052
0 31119eq14afam m Single Home Tank 07 16 15a 78810
031119eq15afam m Single Home Tank 09 02 la
031119eq16afam m Single Home Tank 09 02 2a
031119eq18afam m Single Home Tank 09 02 4a 45948
031119eq19afam m Single Home Tank 09 02 5a
031119eg20afam m Inflow 09 30 1 1733 13118 233 1073 343
0 31119eq21afam m Outflow before ultraviolet treatm ent 09 30 2 698 198 1235 428
0 3 1 119aq22afam m Outflow after ultraviolet treatm ent 09 30 3 1027 228 1269 458
031120eq04afam m Single Home Tank 09 02 3a
0 3 1 121eq04afam m Single Home Tank 09 02 8b
0 3 1 121eq05afam m Single Home Tank 09 02 8b2 (twc runs through HLB) 116
031121eq07afam m non-silinized G lassw are wwtp 10 27 la 1014 7248 134 704 215
0 3 1 121eq08afam m non- silinized G lassw are wwtp 102 7  1b 1069 7046 178 823 219
031121eq09afam m Silinized G lassw are wwtp 10 27 2a 605 6872 73 554 183
0 3 1 121eq10afam m silinized g lassw are wwtp 10 27 2b 683 7097 80 502 182
031121eq15afam m Frenctitown Hiqti schoolfseptic tank) 1 0 3 0  1 3999 5713 151
0 3 1 121eq20afam m Frenditown Hiqti sctioolfseptic tank) 11 05 1 4994 18712 219
031121eq27afam m Single Home Tank 9 02 2b
031121eq28afam m Single Home Tank 09 02 10a 4911
031121eq29afam m Single Home Tank 09 02 10b 5359
031121eq30afam m Single Home Tank 09 02 10b2 (double runs through HLB) 2439
030723m b08afamm Single Home Tank 07 01 03 3b 10%
030723m b09afamm Single Home Tank 07 01 03 3b 50%
030723mb1 Oafamm Single Home Tank 07 01 03 3b 100%
030724m b03afamm Single Hom e Tank e.17.03-5a 13873
030724m b04afamm Single Home Tank 6.17 03-5b (spiked) 8589 23543 19851
030724m b08afamm Single Home Tank 6.17 03-7a 7911
030724m b09afamm Single Home Tank 6.17 03-7b spiked 9940 77314
Single Home Tank 09 02 8b
031121eq05afam m Single Home Tank 09 02 8b2 (two runs through HLB) 116
Blanks= BDL
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APPENDIX 8 (continued).
Pharmaceutical concentrations from septic tank effluent, adjusted for dilution
M asslvnx Name Type of Sam ple Date and sample ID Hydrocodone Ketoprofen Metaformin Nicotine Paraxathine
nq/L nq/L nq/L nq/L nq/L
03 1 117ea04afam m Community Tank 06 170 3  la 757 19318
0 3 1 117eo05afam m Community Tank 05 170 3  1b 800 21037
0 3 1 117ea06afam m Community Tank 06 17 03 2a 1110 22200
031117ea07afam m Community Tank 05 17 03 2b 1090 19706
031117epOBafamm Community Tank 06 17 03 3a 532 24747
031117ea09afam m Community Tank 06 17 03 3b 884 36593
031117eo10afam m Community Tank 06 17 03 4a 302 25755
0 31117ea11afam m Community Tank 06 17 03 4b 1112 13831
031117efl12afamm Community Tank 06 17 03 6a 7639 13644 371349
031117eal3afam m Community Tank 06 17 03 6b 5610 11057 311395
031117ea14afam m Community Tank 06 17 03 8a 1012224
031117eo15afam m Community Tank 06 17 03 8b {Spiked SOOOug/mL) 708228
G31117eg16afamm Community Tank 06 17 03 9a 501968
031117eg17afam m Community Tank 06 17 03 9b (spiked 1mL 5000ug/mL) 799549
031 1 18egl0afam m Community Tank 06 17 10a 5390 358918
031118egl1afam m Single Home Tank 07 01 la 7077
031118ea12afam m Single Home Tank 07 01 2a 142 765860
0311186Ql3afam m Single Home Tank 07 01 2b (lots Stuck on vial) 129 12939 765103
031118ea14afam m Single Home Tank 07 01 2b2 (890uL of mobile phase to redissolve) 36 4475 33741
031118eg15afam m Single Home Tank 07 01 3a 5066 143693
031118eq16afam m Single Home Tank 07 01 4a 15367 366299
031118eq17afam m Single Home Tank 07 01 5a 162361
031 1 18eq18afam m Single Home Tank 07 01 6a 47807
031118eq19afam m Single Home Tank 07 01 7a 164426
031118eg20afam m Single Home Tank 07 01 8a 5506 205014
031118eq21afam m Single Home Tank 07 01 9a 201708
031118eg22afam m Single Home Tank 07 01 10a 2233 56713
031118eq23afam m Single Home Tank 07 16 la 13 1241 29381
031118eq24afam m Single Home Tank 07 16 2a 23030 405693
031118eq25afam m Single Home Tank 07 16 3a 12628 216711
031118eq26afam m Single Home Tank 07 16 4a 5919 513540
031119eq04afam mA Single Home Tank 07 16 5a 6796 125801
031 1 19eq05afam m Single Home Tank 07 16 6a 97682
031 1 19eq06afam m Single Home Tank 07 16 7a 100781 165976
031119eq08afam m Single Home Tank 07 16 9a 74036
031119eq09afam m Single Home Tank 07 16 10a 326904
0 3 1 119eg10afam m Single Home Tank 07 16 11a 715 237557
0 3 1 119eq1 lafam m Single Home Tank 07 16 12a 4696 420505
031119eq12afam m Single Home Tank 07 16 13a 10344
031119eq13afam m Single Home Tank 07 16 14a
031119eq14afam m Single Home Tank 07 16 15a 169 17571 479941
03l119eq15afam m Single Home Tank 09 02 1 a 185322
031119eq16afam m Single Home Tank 09 02 2a 107279
031119eq18afam m Single Home Tank 09 02 4a 25602 910101
031119eq19afam m Single Home Tank 09 02 5a 191402
031119eq20afam m Inflow 09 30 1 2687 4132 183393
031119eq21afam m Outflow before ultraviolet treatm ent 09 30 2 1676
031119eq22afam m Outflow after ultraviolet treatm ent 09 30 3 2049
0 3 1 120eq04afam m Single Home Tank 09 02 3a 113082
0 3 1 121eq04afam m Single Home Tank 09 02 8b 67672
0 3 1 121eq05afam m Single Home Tank 09 02 8b2 (two runs through HLB) 40881
0 3 1 121eq07afam m non-silinized G lassw are wwtp 10 27 la 1377 2370 75859
0 3 1 121eq08afam m non- silinized G lassw are wwtp 10 27 1b 1485 2368 84001
031121eq09afam m Silinized G lassw are wwtp 10 27 2a 1118 1734 89810
0 3 1 121eql0afam m silinized glassw are ww4p 10 27 2b 1076 1732 109452
031121eq15afam m Frenchtown High schoolfseptic tank) 10 30 1 783 87774
0 3 1 121eq20afam m Frenchtown High schoolfseptic tank) 11 05 1 1002 84130
0 3 1 121eq27afam m Single Home Tank 9 02 2b 41407 69202
0 3 1 121eq28afam m Single Home Tank 09 02 10a 104211 944 69033
0 3 1 121eq29afam m Single Home Tank 09 02 10b 147640 871 71843
0 3 1 121eq30afam m Single Home Tank 09 02 10b2 (double runs through HLB) 196434
030723m b08afam m Single Home Tank 07 01 03 3b 10% 141516
030723m b09afam m Single Home Tank 07 01 03 3b 50% 7882 338488
030723mb1 Oafamm Single Home Tank 07 01 03 3b 100% 175125
030724m b03afam m Single Home Tank 6 17.03-5a 15 8599 91213
030724m b04afam m Single Home Tank 6 17.03-5b (spiked) 13 12795 179438
030724m b08afam m Single Home Tank 6 17 03-7a 589634
030724m b09afam m Single Home Tank 6 17.03-7b spiked 899108
03 1 121eq04afam m Single Home Tank 09 02 8b 67672
03 1 121eq05afam m Single Home Tank 09 02 8b2 (two runs through HLB) 40861
Blanks= BDL
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A P P E N D IX  8 (con tinued) .
Pharmaceutical concentrations from septic tank effluent, adjusted for dilution
D ate an d  sam p le  ID Ranitidine Sulfam ethoxazole Trimethoprim Warfarin
ng/L ng/L ng/L nq/L
06  17 03  l a 364
06  17 03 1b 456
06  17 03  2 a 286
06  17 03  2b 237
06  17 03 3a 145
06 17 03 3b
06  17 03  4a 1901
06  17 03  4b 682
06  17 03  6 a 50
0 6  17 03  6b 103 44
06  17 03  8a 3987
06  17 03  8 b  (Spiked 5000ug/m L) 45362 4724
06  17 03  9 a
06 17 03  9b  (spiked Im L  5000ug/m L) 193439
06 17 10a 7241
07 01 l a
07 01 2 a 3603
07 01 2 b  (lots s tuck  on vial)
07 01 2b2  (890uL of m obile p h a s e  to redissolve)
07 01 3a 3910
07  01 4 a 3293
07  01 5a
07  01 6 a 12618
07 01 7a 13253
07 01 8 a 4837
07 01 9a 5 4314
07 01 10a 2354
07 16 l a 7026
07 16 2a 3450
07 16 3a 18529
07 16 4 a 11666
07 16 5a
07 16 6 a 2205
07 16 7a 18263
07  16 9 a
07 16 10a 50 4732
07 16 11a 12048
07 16 12a
07 16 13a 8380
07 16 14a 985 64767 6419
07 16 15a 14322
09  02 l a 16437
09  02 2a 259 2462
09  02 4a 7014
09  02 5a 23297
09  30 1 213 1686
0 9  30 2 268 464
0 9  30 3 297 115
09  02 3a 12592
09  02 8b 1811
09  02  8b2  (two runs th rough HLB)
1 0 2 7  l a 30 251 1444
1 0 2 7  1b 119 234 208 1799
10 27 2 a 84 165 171 1193
10 27 2b 121 208 250 1354
10 30  1 5 4266 628 1217
11 05  1 21 29690 1472 1203
9 02 2b -52 193
09  02 10a 3340
09  02  10b 5840
09  02  10b2 (double runs  through HLB)
07 01 03  3b 10%
07 01 03  3b  50%
07 01 03  3b  100%
6.17  03 -5a 129
6 .17 .03 -5b  (spiked) 101 25619
6 17 03 -7a 1590 1581
6 .17 .03 -7b  spiked 1527 65041
09  02  8b 1811
09  02 8b2 (two runs th rough HLB)
Blanks= BDL
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APPENDIX 9.
Pharmaceutical Concentrations of ground water and surface water, adjusted for dilution
M asslvn*  N a m e D a te  a n d  sa m p le  identification A ce tam in o p h en A nbpvnne C affiene C a rb a m a z e p in e C im ebd ine C o b n in e
nq/L ng/L ng/L ng/L ng/L
0 3 1 1 1 9 e a 2 4 a fa m m DW Q  sa m o ie s  (L ega l ID= W 1 31919C ) 10 15 l a -  H aw thorne BDL BDL 44 0 BDL BDL 4
0 3 1 1 1 9 e a 2 5 a fa m m DW Q  sa m o ie s  (L ega l 10= U l 3 2 0 2 5 0 ) 10 15 2a* T ow er a n d  S purg in BDL BOL 2 06 .9 BDL BDL 7
0 3 1 1 1 9 e a 2 6 a fa m m DW Q  sa m p le s  (L ega l 10= W 132026B ) 10 15 3 a -K e lly  isi A nd S purg in BDL BOL BDL BDL BDL BOL
0 3 1 1 1 9 e a 2 7 a fa m m OW Q  sa m p le s  (L egal 10= W 13 2 0 2 6 0 ) 10 15 4a* H um ble and  M ount BDL BOL 42 .0 13 BDL BDL
0 3 1 1 2 0 e q 0 5 a fa m m D W Q  sa m p le s  (Legal 10= W 1 3 1 9 3 0 0 ) 10 15 5a- (S p ik ed  1 mL 50  ng/m L) 8 440 BDL 12175 561 95 6
0 3 1 1 2 0 e g 0 6 a fa m m O W Q  sa m p le s  (Legal 10= W 13 1 9 3 0 0 ) 10 15 Sb- C en tra l a n d  R e se rv e BOL BOL 6 1 .0 BOL BDL 1
0 3 1 12 Q eo 0 7 afam m D W Q  sa m p le s  (L egal 10= W 1 5 2 1 29A) 10 15 6 a -  T o u c h e tte  Ln, F rench tow n BDL BDL 85 0 BDL BDL 2
0 3 1 1 2 0 ea0 8 a1 am m D W Q  sa m p le s  (L egal 10= W 1 3 1 9 3 1 0 ] 10 15 7 a -  L archm ont BDL BDL BDL BOL BDL BDL
0 3 1 1 2 1 e a 0 6 a fa m m O W Q  sa m p le s  (L egal 10= W 1 31914C ) 10  15 8 a -A lv in a  P ark BOL BDL 21 2 BDL BLOQ
0 3 1 1 2 1 e q 1 5 a fa m m F renchtow m  Hiqh sch o o l (se p tic  tank) 1 0 /3 0 /2003  1 30998 53664 454 BDL 399 9
0 3 1 1 2 1 e a 1 6 a fa m m F ren ch to w n  High sch o o l (well # 19 ) 10 /30 /2003  2 BOL BDL BOL 78 BDL BDL
0 3 1 1 2 1 e g 1 7 a fa m m F ren ch to w n  High sch o o l (well # 40 ) 10 /30 /2003  3 BDL BDL BDL 59 BDL BDL
0 3 1 1 2 1 e a l8 a fa m m F ren ch to w n  High sch o o l (well # 41 ) 10 /30 /2003  4 BOL BOL BDL 137 BDL BOL
0 3 1 1 2 1 e o 1 9 a fa m m F ren ch to w n  High sch o o l (W ell # 26 ) 1 0 /3 0 /2003  5 BOL BDL BDL 151 BOL BOL
031121  e a 2 0 a fa m m F ren ch to w n  High sch o o l (seo tic  tank ) 11 /0 5 /2003  1 25614 BDL 6 2 1 9 2 262 BOL 4994
0 31121  e a 2 1 a fa m m F ren ch to w n  High sch o o l (well # 19 ) 1 1 /0 5 /2003  2 BDL BDL 16 202 BDL BDL
0 3 1 1 2 1 e a 2 2 a fa m m F ren ch to w n  High sch o o l (well # 40 ) 11 /05 /2003  3 BOL BDL BDL 93 BDL BDL
0 3 1 1 2 1 e a 2 3 a fa m m F ren ch to w n  High sch o o l (well # 41 ) 11 /05 /2003  4 BOL BDL BDL 186 BOL BDL
0 3 1 1 2 1 e a 2 4 a fa m m F ren ch to w n  Hiqh sch o o l (W ell # 26 ) 11 /05 /2003  5 BDL BDL BDL 211 BDL BDL
0 3 1 1 1 9 e a 2 0 a fa m m 09  30  1 525 0 7 9 137607 486 1733 13118
0 3 1 1 1 9 e a 2 1 a fa m m O utflow  befo re  u ltrav io let trea tm en t 09  30  2 BDL BDL 719 470 6 9 6 198
0 3 1 1 1 9 e a 2 2 a fa m m O utflow  afte r u ltraviolet trea tm en t 09  30  3 BOL BDL 616 498 1027 228
0 3 1 1 1 9 e a 2 3 a fa m m Kelly Island  sa m p le  (C lark  Fork dow n stre 09  30  4 BDL BDL 1367 3 BDL 0
0 3 1 1 2 1 e a 2 5 a fa m m 11 06  1 BDL BOL BOL BOL BDL BDL
031121  e g 2 6 a fa m m T ap  w a te r 11 08  2a BOL BDL BDL BDL BDL BDL
M asslv n x  N am e Type D a te  a n d  sa m p le  idenbficabon D ilbazem Ervthfomycin- C o d ien e H yd ro co d o n e K etop ro fen M etaform in
nq/L ng/L nq&
0 3 1 1 1 9 e a 2 4 a fa m m O W Q  sa m p le s  (L egal 10= W 1 31919C ) 10 15 1a- H aw thorne BDL BDL BDL BDL BDL BDL
0 3 1 1 1 9 e a 2 5 a fa m m DW Q sa m p le s  (L egal 10= U 13 2 0 2 5 0 ) 10 IS  2 a -  T ow er a n d  S purg in BDL BDL BDL BDL BDL BOL
0 3 1 1 1 9 e a 2 6 a fa m m O W Q  sa m p le s  (L egal 10= W 132026B ) 10 15 3a- Kelly isl. A nd S purg in BDL BDL BDL BDL BDL BOL
0 3 1 1 1 9 e a 2 7 a fa m m O W Q  sa m o ie s  (L egal 10= W 1 3 2 0 2 6 0 ) 10 15 4a- H um ble and  M ount BDL BDL BDL BDL BDL BDL
0 3 1 1 2 0 eq 0 S afam m D W Q  sa m p le s  (L egal 10= W 131930D ) 10 15 5a- (S p ik ed  1 mL 5 0  ng/m L) 4303 BDL BDL BDL BDL BDL
0 3 1 1 2 0 eq 0 6 a fam m O W Q  sa m o ie s  (L egal 10= W 131930O ) 10 15 5b- C en tra l a n d  R e se rv e BDL BOL BDL BOL BDL BOL
0 3 1 1 2 0 e a 0 7 a fa m m O W Q  sa m p le s  (L egal 10= W 152129A ) 10 15 6 a -  T o u c h e tte  l_n. F rench tow n BDL BDL BDL BDL BOL BDL
0 3 1 1 2 0 e a 0 S a fa m m O W Q  sa m p le s  (L egal 10= W 131931D ) 10 15 7a- L archm ont BDL BDL BDL BDL BOL BOL
0 3 1 1 2 1 e a 0 6 a fa m m O W Q  sa m p le s  (L egal 10= W 1 31914C ) 10 15 8 a -  Alvina P ark BDL BDL BDL BDL BDL BDL
0 3 1 1 2 1 e g 1 5 a fa m m F ren ch to w n  High sc h o o l (s e p b c  tank ) 1 0 /30 /2003  1 BDL 5713 151 BDL BDL BOL
0 3 1 1 2 1 e a 1 6 a fa m m F ren ch to w n  High sc h o o l (well # 19 ) 1 0 /30 /2003  2 BDL BOL BDL BDL BDL BDL
0 3 1 1 2 1 e g 1 7 a fa m m F ren ch to w n  High sc h o o l (well # 40 ) 1 0 /30 /2003  3 BDL BOL BDL BOL BOL BDL
0 3 1 1 2 1 e a 1 6 a fa m m F ren ch to w n  H igh sc h o o l (well # 4 1 ) 1 0 /30 /2003  4 BDL BDL BDL BDL BDL BDL
0 3 1 1 2 1 e a 1 9 a fa m m F ren ch to w n  High sc h o o l (W ell # 26 ) 1 0 /30 /2003  5 BDL BOL BDL BDL BOL BOL
0 3 1 1 2 1 e a 2 0 a fa m m F ren ch to w n  High sch o o l (sep tic  tank ) 1 1 /05 /2003  1 BDL 18712 219 BDL BDL BDL
0 3 1 1 2 1 e a 2 1 a fa m m F ren ch to w n  High sc h o o l (well # 19 ) 1 1 /05 /2003  2 BOL BDL BDL BOL BDL BDL
0 3 1 1 2 1 e g 2 2 a fa m m F ren ch to w n  High sc h o o l (well # 40 ) 1 1 /05 /2003  3 BDL BDL BDL BDL BDL BDL
0 3 1 1 2 1 e q 2 3 a fa m m F ren ch to w n  High sc h o o l (well # 41 ) 1 1 /05 /2003  4 BDL BDL BOL BOL BDL BDL
0 3 1 1 2 1 e g 2 4 a fa m m F ren ch to w n  Hiqh sc h o o l (W ell # 26 ) 1 1 /05 /2003  5 BDL BOL BDL BDL BDL BDL
0 3 1 1 1 9 eq 2 0 a fam m 0 9  30  1 2 3 3  2734911 1073 343 BDL BDL 268 7
0 3 1 1 1 9 e q 2 1 a fa m m O utflow  befo re  u ltrav io let trea tm en t 0 9  30  2 BDL 1235 428 BDL BDL 1676
0 3 1 1 1 9 e a 2 2 a fa m m O utflow  a fte r u ltraviolet trea tm en t 0 9  30  3 BDL 1269 458 BDL BOL 204 9
0 3 1 1 1 9 e q 2 3 a fa m m Kelly Island s a m p le  (C lark Fork  dow n  stre 0 9  30  4 BDL BDL BDL BDL BDL
0 3 1 1 2 1 e q 2 S a fa m m 11 08  1 BDL BDL BDL BDL BDL BDL
031121 e q 26a1am m T ap  w a te r 11 08  2a BDL BDL BDL BDL BDL BDL
BDL= B elow  d e te c b o n  limit
B L O Q sD e te c te d  c o m p o u n d  with a s igna l to n o ise  rabo  > 3 (>S /N =3) b u t b e lo w  limit of g u an titabon
S p ik ed =  C affiene , A c tam in o p h en , c a rb a m a z e p in e .  cim etid ine. d ilbazem . tn m ethoprim
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APPENDIX 9 (continued).
Pharmaceutical Concentrations of ground water and surface water, adjusted for dilution
M asslvnx N am e Nicotine Paraxa th ine Ranitidine Sulfam ethoxazole T nm ethoorim W arfarin
no/L no/L no/L no/L nq/L
0 3 1 1 1 9 ea7 4 afam m DW Q sam p le s  (L eaal 10= W 131919C1 BDL BDL BDL BDL 6 BDL
0 3 1 1 1 9 ea2 5 afam m DWQ sam p le s  (L eaal 10= U13202SD) SOL BDL BDL BDL BOL BOL
0 3 1 1 1 9 ea2 6 afam m DWQ sam p le s  (L eaal 10= W 132026B1 BDL BOL BOL BDL BDL BOL
0 3 1 1 1 9 ea2 7 aram m OWQ sam p le s  (L eaal 10= W 13202601 BDL BDL BDL BDL BDL BDL
0 3 ll2 0 e g 0 5 a ra m rr DWQ sam p le s  (Leaal 10= W 13193001 BDL BOL BDL BOL 258 9 SDL
0 3 1 1 20en0fia fam rr OWQ sam p le s  (Leaal 10= W 131930O ) BDL BOL BDL BOL BDL BDL
0 3 1 1 2 0 e a0 7 a fam rr DWQ sam p le s  (Leaal 10= W 152129A1 BDL BDL BDL BOL BDL BDL
031 1 20eg 0 6 a fam rr DWQ sam p le s  (Leaal 10= W 131931D I SDL BDL BDL BOL BOL BDL
031121ea06afam rT DWQ sam p le s  (Leaal 10= W 131914C1 10 15 8a- Alvina Park BDL BDL BDL BDL BDL BDL
0 3 1 1 2 1 eQ l5 a fam m F renchtow n Hiqh school (sep lic  tank) 10/30/2003 1 783 87773 6341 S 4266 628 1217
0 3 1 1 2 1 eg 1 6 a fam m F renchlow n Hioh school (well #19) 10/30/2003 2 BDL BDL BDL 23 BOL BOL
031 1 2 1 eq 1 7 a fam m F renchtow n Hiqh school (well #40) 10/30/2003 3 BDL BDL 11 SOL BDL
O 31121eq10atam m F renchlow n Hiah school (well #411 10/30/2003 4 BDL BDL BDL 49 BDL BDL
0 3 1 1 2 le q 1 9 a fa m m F renchtow n High schoo l (Well #26) 10/30/2003  5 55 BDL BDL 55 BDL BOL
0 3 1 121eq20afam m F renchlow n High schoo l (sep tic  tank) 11/05/2003  1 1002 84129 8287 21 29690 1472 1203
03112 1 eq 2 1 afam m Frenchtow n High schoo l (.well #19) 11/05/2003  2 BDL BDL BDL 466 BOL BDL
0311 2 1 ea2 2 a fam m Frenchlow n Hiqh schoo l (well #40) 11/05/2003  3 BDL BDL BDL 44 BDL BDL
0 3 1 121eq23afam m Frenchlow n High schoo l (well #41 ) 11 /05/2003  4 BOL BDL BDL BDL BDL
03112 1 eq 2 4 afam m F renchlow n High schoo l (Well #26) 11/05/2003 5 BDL BDL BOL 66 BDL BDL
BDL
0 3 1 1 19eq20afam m 09  30 1 4132 183393 021 BDL 213 1686
0 31 1 1 9 eq 2 1 a fam m Outflow befo re  ultraviolet trea tm en t 09  30 2 BOL BOL BOL 268 464 BDL
0 3 1 1 19eq22afam m O utflow after ultraviolet trea tm en t 09  30 3 BOL BDL BOL 297 115 BOL
0 3 1 1 19eq23afam m Kellv Island sam ple  (C lark Fork down s tream  from W W TP 09  30  4 BDL BDL BDL BDL BDL BOL
0 3 1 121eq25afam m BOL BOL BDL BDL BOL
031121 eq26afam m T ap  w ater BDL BOL BDL BDL
BDL= Below detection  limit
B L O O =D etected  com pound  with a signal to noise ratio > 3 (>S/N=3) but below limit of quantitat
Spiked=  C affiene, A ctam inophen , ca rbam azep in e . cim etidine diitiazem, tnm ethopnm
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